May 1, 2013

TSX Exchange Symbol: RVX

CALGARY, May 1, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) ("Resverlogix") today announced that its Board of Directors has unanimously approved the previously announced Plan of Arrangement ("the Arrangement") to spin-out its subsidiary RVX Therapeutics Inc. ("RVX Therapeutics"). Resverlogix has entered into an Arrangement Agreement with RVX Therapeutics and 1741273 Alberta Ltd., a newly-incorporated company ("Spinco"), which provides for, among other things, the acquisition of RVX Therapeutics by Spinco. Upon completion of the Arrangement, Resverlogix shareholders will own one common share of Resverlogix and will receive one common share of Spinco for each Resverlogix common share held immediately prior to the Arrangement becoming effective.

The Arrangement is subject to customary conditions for a transaction of this nature, which include court and regulatory approvals, including TSX acceptance of the Arrangement and the approval of at least 66.67% of the votes cast by the Resverlogix shareholders present in-person or by proxy at the special meeting of the shareholders of Resverlogix ("the Meeting"). The Meeting will commence at 11 a.m. MDT, May 28, 2013, at the Hyatt Regency Calgary hotel, Imperial Ballroom (1/2/3) at 700 Center Street SE in Calgary, Alberta.

A management information circular containing a complete description of the Arrangement has been sent to these shareholders in connection with the special meeting to approve the Arrangement. The information circular has also been filed on SEDAR.

Resverlogix shareholders of record on April 25, 2013 will be entitled to vote at the Meeting. Subject to all necessary approvals being obtained, it is anticipated that the Arrangement will become effective on or about June 3, 2013. The Toronto Stock Exchange has determined that the Due Bill trading procedure will be used in connection with the distribution of the common shares of Spinco to Resverlogix shareholders pursuant to the Arrangement. Please refer to the information circular for further information. Resverlogix anticipates issuing a press release setting forth the relevant dates for the Due Bill trading procedure.

Pursuant to the Arrangement, Spinco will also be issued royalty preferred shares in the capital of Resverlogix which will provide Spinco with a dividend equal to 6 to 12% of "Net Apo Revenue" as described in the information circular.

As part of the Arrangement, Resverlogix will transfer to Spinco all of the indebtedness of RVX Therapeutics owing to Resverlogix. Resverlogix will also transfer between $5 and $10 million of cash to provide for the initial capitalization of Spinco.

Spinco shares will not be listed on any stock exchange. The Spinco Board will give due consideration in the future as to whether it is in the best interests of shareholders of Spinco that the shares become publicly traded.

There can be no assurances or guarantees that the spin-out will be completed.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer and neurodegenerative diseases and diabetes mellitus. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the completion of the Arrangement and the funds to be transferred from Resverlogix to Spinco. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and other documents we file from time to time with securities regulatory authorities, which are available through SEDAR at www.sedar.com The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. We disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:     

Donald J. McCaffrey
President & CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com

Sarah Zapotichny
Director of Investor Relations
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com

SOURCE: Resverlogix Corp.

Apr 18, 2013

IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease

TSX Exchange Symbol: RVX

CALGARY, April 18, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low HDL and ApoA-I (n=324). These target patients have significant residual risk in major adverse coronary events (MACE) such as heart attack, unstable angina, stroke, revascularization and death, despite standard of care therapy such as statins. The main underlying cause of the residual risk in these patients is atherosclerosis. ASSURE is designed to evaluate the ability of RVX-208 to regress atherosclerotic disease.

"Atherosclerosis regression represents a new paradigm in the treatment of high-risk cardiovascular disease patients," said Donald McCaffrey, president and chief executive officer of Resverlogix. "The completion of the ASSURE trial is a major development milestone for the company. RVX-208 is the first small molecule BET inhibitor that raises the production of ApoA-I to be tested in a landmark IVUS trial."

ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled trial led by the Cleveland Clinic. To assess atherosclerosis regression in ASSURE, all subjects were examined using IVUS. The primary endpoint in ASSURE is to detect a change in percent atheroma volume as determined by IVUS at baseline vs. 26 weeks of treatment. The use of IVUS technology will provide details regarding plaque composition and stability, which is important because both are elements leading to acute coronary syndrome. Secondary endpoints for ASSURE include safety and tolerability of RVX-208, effects of the compound on plasma ApoA-I, HDL-C, HDL-subclasses and non-HDL lipid parameters such as the CRP inflammation marker. Top line data is expected mid-2013.

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. This drug also has the potential to treat other indications, including diabetes mellitus, and neurodegenerative disorders. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple therapeutic indications including cancer and autoimmune diseases. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Apr 8, 2013

Transaction Designed to Enhance Shareholder Value By Unlocking Value of the Epigenetics Platform

TSX Exchange Symbol: RVX

CALGARY, April 8, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) ("Resverlogix") today announced that its Board of Directors has approved a proposal to spin-out its subsidiary, RVX Therapeutics Inc. ("RVX Therapeutics"), which will focus on innovative drug research and development by leveraging its epigenetics platform. RVX Therapeutics will exclude Apolipoprotein A-1 ("Apo A-1") and RVX-208 technologies, rather focusing on multiple therapeutic indications including autoimmune diseases and cancer.

The spin-out is to be implemented by way of a court-approved Plan of Arrangement ("the Arrangement") pursuant to the Business Corporations Act (Alberta). The implementation of the Arrangement will be subject to, among other things, final board approval of the Arrangement and a shareholder vote.

Rationale

The spin-out of RVX Therapeutics reflects the Board of Director's and management's belief that it is in the best interests of shareholders to create a future value for its epigenetics platform and to provide a mechanism for the retention of possible future royalties on RVX-208 sales, depending on the deal structure finally negotiated.

Based on the belief that the RVX-208 program currently accounts for the entire market value of Resverlogix and that the value of the epigenetics platform is unrealized, the spinning out of RVX Therapeutics will facilitate a corporate structure that is more likely to reflect an accurate valuation of the epigenetics platform.

The objective of the spin-out is to split the clinical RVX-208 program (Resverlogix) from the epigenetics platform (RVX Therapeutics). In doing so, this process will create distinct corporate environments such that Resverlogix is structurally ready for acquisition while RVX Therapeutics' future value could be realized through a licensing and/or partnering business model.

This has the potential to unlock the future value for RVX Therapeutics via research and development of the epigenetic mechanism and establishes a potential royalty stream from RVX-208. Enhanced long-term shareholder value is provided through direct valuations related to any future licensing and partnering deals.

In addition, the new structure will minimize future dilutions should either corporation require additional equity capital.

Resverlogix will continue to focus on the clinical development of RVX-208, its small molecule for the treatment of atherosclerosis through therapeutic increases in Apo A-1. In addition, Resverlogix will continue with its RVX-208 related clinical trial for diabetes and the soon to launch Alzheimer's disease clinical trial.

RVX Therapeutics will focus on innovative drug research and development by leveraging its epigenetics platform in multiple diseases including autoimmune and oncology, excluding Apo A-1 and RVX-208 technology.

It is anticipated that the directors and senior officers of RVX Therapeutics will continue to consist of current directors and senior officers of Resverlogix.

Resverlogix shareholders to receive one share in each of the two companies

Under the terms of the Arrangement, Resverlogix's shareholders will receive shares of a newly incorporated company ("Spinco") that will own all of the shares of RVX Therapeutics on a basis that is proportional to their interest in Resverlogix. Every Resverlogix shareholder will receive one share in Spinco for every share held in Resverlogix at the effective date.

Every Resverlogix warrant holder at the effective date will receive one warrant in Spinco for every warrant held in Resverlogix. The exercise price of Resverlogix warrants would be reduced in accordance with the terms of the applicable warrant by an amount on a per share basis to reflect the fair market value of Spinco and the reduction would be allocated to the exercise price of the replacement Spinco warrants. If a Resverlogix warrant holder wishes to participate in the Arrangement and receive common shares of Spinco at the effective date, the warrant holder will need to exercise their Resverlogix warrants prior to the effective date of the Arrangement to acquire Resverlogix common shares.

Shares of Spinco will not be listed on an exchange initially, however the Board of Directors will give due consideration to whether it is in the best interests of shareholders of Spinco that the shares of Spinco are listed and at what time.

The implementation of the Arrangement will be subject to, among other things, board, shareholders, court and regulatory approvals, including TSX acceptance of the Arrangement.

Resverlogix must hold a special meeting of shareholders to approve the Arrangement. The record and meeting dates are anticipated to be on or around April 25, 2013 and May 28, 2013, respectively. A management information circular containing a complete description of the Arrangement and a description of tax implications to shareholders will be sent to shareholders of Resverlogix in connection with the special meeting to approve the Arrangement.

There can be no assurances or guarantees that the spin-out will be completed.

Resverlogix will host a live conference call and webcast with Q&A at 11 a.m. MDT, April 8, 2013.

Webcast Link:

http://services.choruscall.ca/links/resverlogix130408.html

Conference call-in numbers:

Canada & USA Toll Free Dial In:  1-800-319-4610
Outside of Canada & USA call:  +1-604-638-5340

About Resverlogix Corp.

Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix' epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Follow us on our blog at http://www.resverlogix.com/blog/

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the structure and timing of the proposed transaction, future royalties on RVX-208, future value of RVX Therapeutics and the epigenetics platform and future research and development activities. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and other documents we file from time to time with securities regulatory authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. We disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:     

Donald J. McCaffrey
President & CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com

Sarah Zapotichny
Director of Investor Relations
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com

SOURCE: Resverlogix Corp.

Mar 11, 2013

TSX Exchange Symbol: RVX

CALGARY, March 11, 2013 /CNW/ - Resverlogix Corp. (TSX:RVX) ("Resverlogix") today announced that it has entered into an Amended and Restated Loan Agreement with Citibank, N.A. ("Citibank") increasing the previously announced loan granted to Resverlogix by Citibank from $25 million to $38.8 million.. The loan is repayable upon maturity on August 28, 2017 and may be repaid in whole or in part after August 27, 2013 without penalty. Interest on the loan is payable annually in arrears at 4.5% per annum until August 27, 2013 and thereafter at a rate equal to Canadian one-year LIBOR swap rate plus 3.14%, to be reset annually. The loan is secured by an irrevocable $38.8 million Standby Letter of Credit (the "Letter of Credit") arranged by Eastern Capital Limited ("Eastern") which will be maintained until maturity of the loan.

In connection with the Letter of Credit, Resverlogix has agreed to indemnify Eastern for all liabilities, costs and expenses arising from any payments made to Citibank under the Letter of Credit and Resverlogix has pledged its issued patents and certain tax losses and pools to Eastern as security for its obligations under the indemnity. Resverlogix also issued an additional 728,640 share purchase warrants to Eastern in connection with the loan increase and will pay a guarantee fee to Eastern in the amount of 0.03% per annum on the average daily aggregate principal amount of the issued and undrawn Letter of Credit. Each warrant is exercisable at a price of $2.38 for a period of five years. Eastern Capital holds 13,200,000 shares of Resverlogix which represents 17.8% of the 74,225,183 common shares outstanding before giving effect to any outstanding warrants.  After giving effect to the transaction, assuming all warrants are exercised, Eastern will hold 15,248,640 shares of Resverlogix representing 19.99% of Resverlogix's issued and outstanding common shares based on shares outstanding as at today's date. Resverlogix is exempted from formal valuation and minority approval requirements of applicable securities laws on the basis that neither the fair market value of, nor the fair market value of the consideration for, the transaction, insofar as it involves Eastern, exceeds 25% of Resverlogix's market capitalization.

Resverlogix intends to use the net proceeds from the loan to fund research and development activities, general and administrative expenses, increased working capital and other general corporate purposes.  The transaction was unanimously approved by Resverlogix's board of directors.

"We are pleased to expand our partnership with Citibank and Eastern on this unique transaction that offers an attractive cost of capital and freedom to repay the loan in whole or in part at any time after August 27, 2013 with minimal dilution," stated Donald McCaffrey, President and CEO of Resverlogix.

About Resverlogix Corp.

Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix' epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com . Follow us on our blog at http://www.resverlogix.com/blog/.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the use of proceeds of the offering. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and other documents we file from time to time with securities regulatory authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. We disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Jan 31, 2013

TSX Exchange Symbol: RVX

CALGARY, Jan. 31, 2013 /CNW/ - At the request of Market Surveillance, Resverlogix management has been requested to comment on the recent steady climb in the stock price. Management is unaware of any single factor for the increase. However we believe that the combination of a recent FDA approval of a competitive cholesterol management agent, mipomersen, and the anticipated pending completion of our Phase 2b ASSURE clinical trial may be primarily responsible for the increased activity. 

About Resverlogix
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Follow us on our blog at http://www.resverlogix.com/blog/

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Oct 16, 2012

TSX Exchange Symbol: RVX

CALGARY, Oct. 16, 2012 /CNW/ - Resverlogix Corp. (TSX:RVX) today announced that it has initiated an exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism. The trial is conducted in collaboration with Baker IDI Heart & Diabetes Institute in Melbourne, Australia, and it will examine insulin secretion, insulin sensitivity and other parameters of importance in individuals with pre-diabetes mellitus. Twenty patients will be enrolled in Australia, with data expected in the first half of 2014.

The foundation of this trial builds upon the actions of RVX-208 and the knowledge that this compound triggers a key epigenetic pathway resulting in enhanced ApoA-I protein production to raise the body's level of functional HDL particles. The effect of newly created ApoA-I/HDL may help to preserve pancreatic cells that make and secrete insulin. Increased abundance of insulin in subjects with pre-diabetes mellitus may prevent or substantially delay the progression towards diabetes mellitus. The estimated trial expense will be less than $1MM CDN with an approximate split in costs of 50/50 between Resverlogix and the Baker IDI Heart & Diabetes Institute.

"Diabetes mellitus is the most common endocrine disease in the world," said Dr. Norman Wong, Chief Scientific Officer, Resverlogix. "The prevalence of this disease is rising at epidemic rates. A primary defect in diabetes mellitus is that the patient's pancreas cannot provide enough insulin for the body, thus leading to increased blood glucose levels. Diabetes mellitus can lead to severe sequelae such as kidney disease, heart disease, disorders of the nerves and blindness. Altering the natural course of the disease could be of great benefit to patients.

"This planned exploratory trial is an important prerequisite to potentially expand the indications for RVX-208 to type 2 diabetes mellitus."

About RVX-208

RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It is currently in clinical study for the treatment of atherosclerosis. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of ApoA-I, the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. RVX-208 is currently being evaluated in phase 2b studies for its ability to reverse and/or stabilize atherosclerotic disease. The drug candidate also has the potential to treat other indications, including neurodegenerative disorders and diabetes mellitus.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Sep 26, 2012

IVUS data will evaluate plaque regression in patients with Coronary Artery Disease

TSX Exchange Symbol: RVX

CALGARY, Sept. 26, 2012 /CNW/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients. ASSURE will evaluate the ability of RVX-208, Resverlogix's BET protein inhibitor, to regress atherosclerotic disease versus placebo using intravascular ultrasound (IVUS) technology in patients with coronary artery disease (CAD).

"Completing enrollment of the ASSURE clinical trial marks another major milestone for Resverlogix as we aim to demonstrate the efficacy of RVX-208 in atherosclerotic plague regression," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "RVX-208 stimulates production of ApoA-I, increasing the functional HDL particles required for reverse cholesterol transport. We expect to announce top-line data from ASSURE in H1 2013."

ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial led by the Cleveland Clinic. The primary trial endpoint will be measurement of atheroma volume reduction from baseline to 26 weeks measured by IVUS. Secondary objectives for ASSURE are evaluating the safety and tolerability of RVX-208 and effects of RVX-208 on HDL and non-HDL lipid parameters. Using IVUS data, we will also assess changes in plaque stability, an important factor affecting risk of myocardial infarction.

About RVX-208

RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It is currently in clinical study for the treatment of atherosclerosis. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of ApoA-I, the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. Because they are newly produced, these functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. RVX-208 is currently being evaluated in phase 2b studies for its ability to reverse and/or stabilize atherosclerotic disease. The drug candidate also has the potential to treat other indications, including neurodegenerative disorders.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune and neurodegenerative disorders. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Aug 28, 2012

-- Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period --
-- Results from ASSURE Study Expected H1 2013, Using IVUS to Measure Regression of Atherosclerotic Plaque --

TSX Exchange Symbol: RVX

MUNICH and CALGARY, Aug. 28, 2012 /CNW/ - Resverlogix Corp. (TSX: RVX) today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of the SUSTAIN trial, a phase 2b clinical study. SUSTAIN also successfully met secondary endpoints, showed increases in levels of Apo-AI (p=0.002) and large HDL particles (p=0.02), both believed to be important factors in enhancing reverse cholesterol transport activity. The SUSTAIN trial also showed that increases in alanine aminotransferase (ALT) reported in previous trials were infrequent and transient with no new increases observed beyond week 12 of the 24-week trial.

The SUSTAIN trial was directed by a clinical steering committee chaired by Dr. Steven Nissen with Dr. Stephen Nicholls serving as Principal Investigator. The committee has approved release of topline findings pending submission of full trial results for publication in a peer-reviewed medical journal.

"Successful completion of the SUSTAIN trial provides Resverlogix with important data regarding improvement in the functionality of the HDL produced by RVX-208," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "Safety data from SUSTAIN reconfirm our belief that early liver signals witnessed in this and previous trials were of a transient nature," Mr. McCaffrey added. "The data support that RVX-208 is suitable for chronic use. The value of this knowledge will benefit our entire epigenetic and bromodomain research program by showing safe versions of epigenetic regulating molecules are indeed achievable. We believe that based on the collective knowledge gained from our recent trials, our company is well positioned as we approach the key plaque regression data expected in our ongoing ASSURE trial."

The phase 2b SUSTAIN trial was conducted in South Africa and led by investigators at the Cleveland Clinic. The study enrolled 176 patients with established atherosclerotic cardiovascular disease (CVD) and low high-density cholesterol (HDL-C). The primary purpose of the SUSTAIN trial was to measure changes in HDL, Apo-AI and other lipid parameters compared with placebo, while also assessing safety over an extended treatment period in the patient population with the largest response to RVX-208 in the phase 2 ASSERT trial. The increase in HDL and Apo-AI observed in the 24-week SUSTAIN trial represents a notable increase over the respective HDL and Apo-AI values reported in the 12-week ASSERT trial.

Epigenetics

Epigenetics is the study of processes that enable information encoded in DNA to be expressed. Although DNA encodes the genes, by itself DNA cannot use this data. To use the data within DNA, it must work in concert with proteins. An essential aspect in this collaborative process is that both DNA and proteins are packaged together into chromosomes that reside within the cell's nucleus. There are thousands of different genes encoded within DNA, and, to enable expression of these genes when called upon by the cell requires epigenetic processes. One of the key epigenetic processes involves modification of chromosomal proteins by acetylation, methylation or phosphorylation, each of which is regulated by specific enzymes. These modified entities serve as bait for other proteins, including BET proteins, to bind to, or "read," these modifications ("the epigenetic code"). As the BET proteins bind, they recruit additional proteins to regulate gene activity. When the gene becomes active, it leads to synthesis of messenger ribonucleic acid (mRNA) followed by translation of mRNA into a specific protein. In the past decade, progress has been made in understanding the role of epigenetics in human disease. This in-depth understanding has led to the development of medicines directed toward cancer, such as DNA methylation inhibitors and HDAC inhibitors. The discovery that RVX-208 is a BET bromodomain inhibitor adds new momentum to the promise of epigenetic mechanisms as a rich source of new medicines.

About RVX-208

RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It is currently in clinical study for the treatment of atherosclerosis. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of ApoA-I, the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. Because they are newly produced, these functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. RVX-208 is currently being evaluated in phase 2b studies for its ability to reverse and/or stabilize atherosclerotic disease. The drug candidate also has the potential to treat other indications, including neurodegenerative disorders.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune and neurodegenerative disorders. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Aug 27, 2012

TSX Exchange Symbol: RVX

CALGARY, Aug. 27, 2012 /CNW/ - Resverlogix Corp. (TSX: RVX) today announced that it has entered into a $25 million Loan Agreement with Citibank, N.A. ("Citibank"). Resverlogix received the $25 million upon closing of the loan. The loan is repayable upon maturity on August 24, 2017 and may be repaid in whole or in part after August 23, 2013 without penalty. Interest on the loan is payable annually in arrears at 4.5% per annum for the first year of the loan and thereafter at a rate equal to Canadian one-year LIBOR swap rate plus 3.14%, to be reset annually. The loan is secured by an irrevocable $25 million Standby Letter of Credit (the "Letter of Credit") arranged by Eastern Capital Limited ("Eastern") which will be maintained until maturity of the loan.

In connection with the irrevocable Letter of Credit, Resverlogix has agreed to indemnify Eastern for all liabilities, costs and expenses arising from any payments made to Citibank under the Letter of Credit and Resverlogix has pledged its issued patents and certain tax losses and pools to Eastern as security for its obligations under the indemnity. Resverlogix also issued 1,320,000 share purchase warrants to Eastern and will pay a guarantee fee to Eastern in the amount of 0.03% per annum on the average daily aggregate principal amount of the issued and undrawn Letter of Credit. Each warrant is exercisable at a price of $1.58 for a period of five years. The expiry date of the warrants is August 27, 2017. Before giving effect to the transaction, Eastern Capital holds 13,200,000 shares of Resverlogix which represents 17.8% of the 74,210,483 common shares outstanding.  After giving effect to the transaction, assuming all warrants are exercised, Eastern will hold 14,520,000 shares of Resverlogix representing 19.2% of Resverlogix's issued and outstanding common shares based on shares outstanding as at today's date. Resverlogix is exempted from formal valuation and minority approval requirements of applicable securities laws on the basis that the fair market value of the warrants does not exceed 25% of Resverlogix's market capitalization.

Resverlogix intends to use the net proceeds from the loan to fund research and development activities, general and administrative expenses, increased working capital and other general corporate purposes.  The transaction was unanimously approved by Resverlogix's board of directors.

"We are pleased to partner with Citibank and Eastern on this unique transaction that offers an attractive cost of capital and freedom to repay the loan in whole or in part at any time after August 23, 2013 with minimal dilution," stated Donald McCaffrey, president and chief executive officer of Resverlogix.

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix's epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune and neurodegenerative disorders. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the use of proceeds of the offering. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and other documents we file from time to time with securities regulatory authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. We disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

SOURCE: Resverlogix Corp.

Jul 16, 2012

TSX Exchange Symbol: RVX

Dr. Bengt Winblad Appointed Chairman of the Clinical & Scientific Advisory Board

Alzheimer's Association International Conference, Vancouver BC, July 16, 2012 /CNW/ - Resverlogix Corp. (TSX:RVX) today announced the formation of a clinical & scientific advisory board to support the clinical development of its lead drug candidate RVX-208 and follow-on bromodomain inhibitors in neurodegenerative diseases such as Alzheimer's disease, mild cognitive impairment and other dementias. The board, chaired by Dr. Bengt Winblad, will provide insight and guidance on all aspects of the development program.

"We believe cardiovascular and neurodegenerative health is linked by lipoproteins such as Apolipoprotein A-I (ApoA-I)," said Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix. "A clinical program will further our understanding of how RVX-208, an epigenetic BET bromodomain inhibitor which increases production of Apo A-I, may affect neurodegenerative diseases such as early dementia or mild cognitive impairment."

Donald McCaffrey, president and chief executive officer of Resverlogix, added, "RVX-208 is the first BET bromodomain inhibitor that has emerged from Resverlogix' epigenetic drug discovery platform and moved into the clinic. It is currently in Phase 2b clinical development in patients with high-risk cardiovascular disease and we are eager to evaluate it and our other BET inhibitor compounds in other disease states."

Bengt Winblad, M.D., Ph.D., professor of geriatric medicine and chief physician at the Karolinska University Hospital, said, "Recent studies are providing evidence of the link between poor cognition, memory and low levels of cardio-protective factors such as ApoA-I. I am looking forward to working with Resverlogix and studying RVX-208 in patients with neurodegenerative diseases."

Resverlogix plans to initiate a Phase 2 trial of RVX-208 in patients with mild cognitive impairment in the second half of 2013.

Appointed members of the clinical & scientific advisory board include:

Bengt Winblad, M.D., Chairman: Dr. Winblad is professor of geriatric medicine and chief physician at the Karolinska University Hospital, Huddinge and the Karolinska Institute in Stockholm, Sweden. Professor Winblad is co-chair of the European Alzheimer Disease Consortium (EADC) and chairs the Medical Scientific Advisory Panel of the Alzheimer Disease International (ADI). In 2009, Dr. Winblad was ranked the world's most prolific researcher in the Alzheimer's disease field (J Alzheimer's Disease 2009).

Jeff Cummings, M.D., Sc.D.: Dr. Cummings is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and Cleveland. Dr. Cummings received the Ronald and Nancy Reagan Research Award from the National Alzheimer's Association in 2008.

Henrik Zetterberg, M.D., Ph.D.: Dr. Zetterberg is professor of neurochemistry at the University of Gothenburg. He was a Fulbright Scholar and research fellow in neurology at the Harvard Institutes of Medicine, Boston between 2004 and 2005. Dr. Zetterberg is an established leader in the field of neurochemistry, biomarkers and diagnostics.

Rada Koldamova, M.D., Ph.D.: Dr. Koldamova is an associate professor and lead researcher at the School of Public Health, University of Pittsburgh's Koldamova & Lefterov lab. Her interest is in cellular and molecular mechanisms of neurodegeneration, the role of ABCA1 transporter and apolipoproteins A-I and E in the pathogenesis of Alzheimer's disease.

About RVX-208
RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains. It is currently in clinical study for the treatment of atherosclerosis. RVX-208 functions by removing atherosclerotic plaque by a process called reverse cholesterol transport (RCT). RCT is the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of ApoA-I, the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. Since new, functional HDL particles are flat and empty they can efficiently remove plaque and stabilize or reverse atherosclerotic disease. RVX-208 is currently being evaluated in Phase 2b studies for its ability to reverse and/or stabilize atherosclerotic disease. RVX-208 also has the potential to treat other indications including neurodegenerative disorders.

About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company with an epigenetic platform technology that modulates protein production. Resverlogix is developing RVX-208, a first-in-class small molecule for the treatment of atherosclerosis. RVX-208 is the first BET bromodomain inhibitor in clinical trials. New compounds arising from Resverlogix' epigenetic drug discovery platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases including cancer, autoimmune and neurodegenerative disorders. Resverlogix' common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities, and the potential role of RVX-208 in the treatment of atherosclerosis and neurodegenerative diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

May 9, 2012

TSX Exchange Symbol: RVX

CALGARY, May 9, 2012 /CNW/ - Resverlogix Corp. (TSX:RVX) is pleased to announce that dosing in SUSTAIN, a Phase 2b clinical trial to assess lipid trends and safety of RVX-208, has been completed on schedule. All patients in the Cleveland Clinic led trial had significant cardiovascular disease (CVD) risks.

In SUSTAIN, a 24-week, multi-centered, double-blind, randomized, parallel group, placebo controlled trial, all subjects received standard of care therapy including up to 40 mg atorvastatin (Lipitor) or 20 mg rosuvastatin (Crestor). As recently stated, RVX-208 is the first known BET Bromodomain inhibitor to be studied in humans. It is an orally active small molecule that raises ApoA-I production leading to enhanced reverse cholesterol transport (RCT).  SUSTAIN trial subjects received either RVX-208 (200 mg/day) or placebo for 24 weeks for the purposes of studying a panel of lipid parameters versus baseline.  SUSTAIN is an important component of an expanded clinical program that includes a parallel Phase 2b clinical trial, ASSURE.  The ASSURE trial will utilize intravascular ultrasound (IVUS) to study the important atherosclerotic plaque regressing aspects of RCT. The unique mechanism by which RVX-208 can potentially regress atherosclerotic plaque distinguishes it from all other known drug classes or small molecule candidates in clinical development.  Resverlogix expects to report top line data for SUSTAIN in Q3 2012 and for ASSURE in Q1 2013.

"We have completed dosing in the SUSTAIN trial, right on schedule," stated Donald McCaffrey, president and chief executive officer of Resverlogix. "Data from this trial will be used to assess the safety and efficacy of RVX-208 in a high-risk population with CVD. This population provides an ideal opportunity to test the effects of RVX-208.  We are particularly interested in confirming the safety of RVX-208 in the extended dosing time frame from three to six months."

Allan Gordon, M.D., Ph.D. and senior vice president of clinical development at Resverlogix, added, "the SUSTAIN trial extends the duration of clinical exposure to RVX-208 by 3 months. Not only will this data provide us with important insights into the safety and efficacy of RVX-208, we also expect important new information for the future development of RVX-208."

About RVX-208
RVX-208 is a novel small molecule that targets and inhibits BET Bromodomains. It is the first small molecule of this novel class of compounds in clinical development.  RVX-208 stimulates endogenous ApoA-I production leading to enhanced reverse cholesterol transport (RCT). The main role of ApoA-I is to assist the body's natural defense system against atherosclerosis as ApoA-I performs its function in a normal physiologic process called RCT. This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production to augment RCT is  a highly differentiated approach from all other CVD therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is our primary focus which is to develop novel small molecules that enhance ApoA-I production and remove atherosclerotic plaque. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease, Oncology and Autoimmune diseases. Resverlogix' common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities, the conduct of the SUSTAIN trial and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Apr 23, 2012

This Novel Epigenetic Mechanism Defines an Entirely New Class of Therapeutic

TSX Exchange Symbol: RVX

CALGARY, April 23, 2012 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Our data shows RVX-208 to be an inhibitor of the Bromodomain and Extraterminal Domain (BET) proteins.  RVX-208 acts on BET proteins, including BRD4, a member of the BET-protein family, leading to increased transcription of the ApoA-I gene followed by production of more ApoA-I protein.

ApoA-I is the major protein component of HDL, a class of lipoproteins believed to reduce atherosclerosis through reverse cholesterol transport (RCT).  The ability of RVX-208 to increase ApoA-I makes it the lead candidate in Resverlogix' pipeline for treating atherosclerotic cardiovascular disease.  RVX-208 is an orally active small molecule, the first in a new class of compounds to enter into human clinical trials more than 4 years ago.  Clinical benefits of RVX-208 are currently being explored in two concurrent Phase 2b clinical trials (SUSTAIN and ASSURE), led by Cleveland Clinic.

"The finding that RVX-208 inhibits BET proteins is an important discovery for a wide scientific and medical audience," stated Dr. Norman Wong, Chief Scientific Officer of Resverlogix.  "This discovery is important because BET proteins are key players in 'epigenetics', a critical mechanism for regulating the expression of genes. Epigenetic processes are mediated by proteins, including the BET-proteins, that act in concert with the DNA to make it transcriptionally active or dormant. This epigenetic control of gene expression plays a key role in the development and progression of many human diseases. The knowledge gained from studies of RVX-208 will guide Resverlogix in its search for additional compounds to treat some of these diseases," added Dr. Wong.

"The MoA of RVX-208 has allowed the company to expand the scope of its technology and the potential of its pipeline significantly," stated Donald McCaffrey, President and Chief Executive Officer of Resverlogix. "We have been generating and filing new intellectual property since our discovery, and see the opportunity to initiate licensing and partnering discussions in the areas of atherosclerosis, oncology, autoimmune and Alzheimer's diseases where the MoA plays a pivotal role." Mr. McCaffrey added that, "the value of this discovery was further validated when Dr. James Watson, in his first solo scientific publication since 1972, highlighted the promise of BRD4 as a therapeutic target and in particular, against untreatable cancers."

As previously announced, Resverlogix will be hosting a Conference Call and Webcast today, April 23, 2012, commencing at 11 am EDT to present in further detail the Mechanism of Action of RVX-208.

Link to access the Webcast:
http://services.choruscall.com/links/resverlogix120423.html

Epigenetics
Epigenetics is the study of processes that enable information encoded in DNA to be expressed. Although DNA encodes the genes, by itself DNA cannot use this data.  To use the data within DNA, it must work in concert with proteins.  An essential aspect in this collaborative process is that both DNA and proteins are packaged together into chromosomes that reside within the cell's nucleus.  There are thousands of different genes encoded within DNA and to enable expression of these genes when called upon by the cell requires epigenetic processes.  One of the key epigenetic processes involves modification of chromosomal proteins by acetylation, methylation or phosphorylation, each of which is regulated by specific enzymes.  These modified entities serve as bait for other proteins including BET proteins to bind to or so called "read" these modifications ("the epigenetic code").  As the BET proteins bind, they recruit additional proteins to regulate gene activity.  When the gene becomes active, it leads to synthesis of messenger ribonucleic acid (mRNA) followed by translation of mRNA into a specific protein.  In the past decade, tremendous progress has been made in understanding the role of epigenetics in human disease.  This in depth understanding has led to the development of medicines directed toward cancer, such as DNA methylation inhibitors and HDAC inhibitors. The discovery that RVX-208 is a BET bromodomain inhibitor adds new momentum to the promise of epigenetic mechanisms as a rich source of new medicines.

RVX-208
RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT).  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls is expected to reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ technology platform is the Company's primary focus, developing novel small molecules that enhance ApoA-I production. These vital therapies are focused on addressing the burden of Atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease, Oncology and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Apr 19, 2012

Dr. Stephen J. Nicholls joins as guest speaker

TSX Exchange Symbol: RVX

CALGARY, April 19, 2012 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce for the first time the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Please join us via Conference Call & Webcast on Monday, April 23, 2012, commencing at 11 am EDT. Dr. Stephen J. Nicholls, Heart Disease Theme Leader at the South Australian Health and Medical Research Institute, will join Resverlogix' President and Chief Executive Officer Donald McCaffrey and Chief Scientific Officer Dr. Norman Wong for an in-depth presentation.

Link to access the Webcast:
http://services.choruscall.com/links/resverlogix120423.html

Conference call dial-in numbers:

In other news, Resverlogix is pleased to announce two important presentations. Donald McCaffrey will be presenting on Friday, April 20, 2012 at BioCentury Future Leaders in the Biotech Industry in New York, NY.  On April 21, 2012, Drs. Norman Wong and Peter Young will be presenting at the ATVB HDL Workshop Meeting in Chicago, IL.

About RVX-208
RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT).  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls is expected to reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ technology platform is the Company's primary focus, developing novel small molecules that enhance ApoA-I production. These vital therapies are focused on addressing the burden of Atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease, Oncology and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Feb 8, 2012

TSX Symbol: RVX

CALGARY, Feb. 8, 2012 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that Donald McCaffrey, President & Chief Executive Officer of Resverlogix will be presenting at The 14^th Annual BIO CEO & Investor Conference on February 13, 2012 at 1:30 PM (EST) at the Waldorf Astoria, New York City.

The presentation will be available via live Webcast and subsequent replay at: http://www.veracast.com/webcasts/bio/ceoinvestor2012/01111295.cfm.

Resverlogix will also post the Webcast link to the Events section of their website at: http://www.resverlogix.com/media/events. The archived replay will be available for a period of 45 days following the live event.

About Resverlogix

Resverlogix is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. These vital therapies are focused on addressing the burden of Atherosclerosis and many other important diseases including Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production and thereby raise high density lipoprotein (HDL) for the treatment of Atherosclerosis. Lead drug RVX-208 is currently in two Phase 2b Clinical Trials led by the Cleveland Clinic. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risks including but not limited to those assumptions and risk factors discussed in the Company's Annual Information Form and MD&A for the interim period ended October 31, 2011 which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please contact:

Jan 19, 2012

/This press release is not for dissemination in the United States or through US newswire services./

TSX Symbol: RVX

CALGARY, Jan. 19, 2012 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has entered into an equity distribution agreement (the "Agreement") with JonesTrading Canada Inc. as agent to sell up to 15 million common shares of Resverlogix ("ATM Shares"), solely at Resverlogix's discretion, from time to time at the market prices prevailing at the time of the sales, without discount, during the period that the Agreement remains effective. Pursuant to the Agreement, Resverlogix also appointed JonesTrading Institutional Services LLC and MLV & Co LLC as US agents to sell up to an additional 10 million common shares of Resverlogix, solely at Resverlogix's discretion, from time to time at a fixed price to subscribers in certain jurisdictions outside Canada during the period that the Agreement remains effective. The Agreement will remain effective until November 2013 unless earlier terminated in accordance with its terms. The ATM Shares will be sold by way of transactions that are "at-the-market distributions", including sales on the Toronto Stock Exchange ("TSX") and other existing trading markets in Canada. The timing of any sale of ATM Shares and the number of ATM Shares sold are at Resverlogix's discretion.

The number of ATM Shares sold shall not exceed 10% of the aggregate market value of Resverlogix's common shares as at the last trading day of the month before the month in which the first trade of ATM Shares is made. The number of ATM Shares sold on any trading day shall not exceed 25% of the total trading volume of the common shares on that trading day.

"This arrangement provides us with a flexible and effective mechanism to raise capital in a manner that is complementary to our other potential sources of capital. The Agreement does not obligate us to issue shares now or in the future, nor does it prevent us from entering into other financing or business development arrangements," said Donald J. McCaffrey, President and CEO of Resverlogix.

Concurrent with entering into the equity distribution agreement, Resverlogix has cancelled the standby equity distribution agreement announced on March 29, 2010.

Resverlogix has obtained a final receipt for a short-form base shelf prospectus (the "Base Shelf Prospectus") with the securities commissions in each of the provinces of Canada. Subject to securities regulatory requirements, the Base Shelf Prospectus allows the Company to make offerings of common shares, preferred shares, debt securities, warrants and units comprising any combination of such securities up to an aggregate offering price of CAD$125 million during the period until November 2013 that the Base Shelf Prospectus remains effective. The distribution of ATM Shares pursuant to the Agreement is qualified by the Base Shelf Prospectus, as supplemented by a prospectus supplement, filed on SEDAR and available electronically at www.sedar.com or on request without charge from the Secretary of Resverlogix at Suite 202, 279 Midpark Way S.E., Calgary, Alberta, T2X 1M2 (telephone (403) 254-9252).

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company's securities in the United States.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. These vital therapies are focused on addressing the burden of atherosclerosis and many other important diseases including Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1 production and thereby raise high density lipoprotein (HDL). Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward-looking information relating to the volume, timing and other terms of any distribution of common shares pursuant to the Agreement. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risks including but not limited to those assumptions and risk factors discussed in the Company's Annual Information Form and MD&A for the interim period ended October 31, 2011 which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For Further Information, please contact:

Nov 29, 2011

/This press release is not for dissemination in the United States or through US newswire services./

TSX Exchange Symbol: RVX

CALGARY, Nov. 29, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that it has closed its previously announced private placement to subscribers in certain jurisdictions outside Canada of 14,819,476 common shares at a price of $1.18 per common share for gross proceeds of $17.5 million. The shares are subject to a four month hold period.

Eastern Capital Limited subscribed for 13,200,000 common shares and NGN BioMed Opportunity II, LP subscribed for 1,619,476 common shares.

The securities to be issued under the offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities in the United States.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

Nov 28, 2011

TSX Exchange Symbol: RVX

CALGARY, Nov. 28, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled. The Cleveland Clinic leads this trial in which all subjects have established atherosclerotic cardiovascular disease (CVD) and low high-density cholesterol (HDL-C). In SUSTAIN, all subjects will receive standard of care therapy that includes up to 40 mg atorvastatin (Lipitor) or 20 mg rosuvastatin (Crestor).  Despite the standard of care therapy in the SUSTAIN population, the risk of recurrent CVD events remains exceedingly high. Thus this patient population presents an ideal opportunity to test the effects of placebo vs. RVX-208 (200 mg/day) an orally active small molecule that raises ApoA-I production and thereby increases HDL-C. SUSTAIN is a 24-week, multi-center, double-blind, randomized, parallel group, placebo controlled clinical trial to assess lipid trends and safety of RVX-208.  Additionally, other biomarkers of reverse cholesterol transport (RCT) will be examined.  The primary endpoint of SUSTAIN is the change in HDL-C from baseline after receiving RVX-208 for 24 weeks vs. placebo. Secondary endpoints include change in ApoA-I, LDL-C, non-HDL-C, apoB, TG and HDL subclasses. Resverlogix expects top line data by late 2012.

"The speed of patient enrollment for SUSTAIN has exceeded our expectations," stated Donald McCaffrey, President and Chief Executive Officer of Resverlogix. "The important goals in SUSTAIN are to show safety and lipid altering effects of RVX-208 in subjects with atherosclerotic CVD and low HDL-C given standard of care therapies. Results from SUSTAIN will help to identify a patient population that will likely benefit the most from the actions of RVX-208 on atherosclerotic CVD", Mr. McCaffrey further commented.

About RVX-208
RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL. The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT). This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities, the conduct of the SUSTAIN trial and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Nov 23, 2011

/This press release is not for dissemination in the United States or through US newswire services./

TSX Exchange Symbol: RVX

CALGARY, Nov. 23, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that it has entered into a Placement Agent Agreement with MLV & Co to act as agent on a best efforts basis for a private placement to subscribers in certain jurisdictions outside Canada of up to 14,819,476 common shares at a price of $1.18 per common share for gross proceeds of up to $17.5 million. The shares will be subject to a four month hold period.

The agent has received signed subscription agreements from investors representing the proposed entire amount of the offering. Eastern Capital Limited will purchase 13,200,000 common shares of the Company pursuant to the offering which represents 17.8% of the 74,097,383 common shares outstanding after giving effect to the offering.

Resverlogix intends to use the net proceeds from the offering to fund research and development activities, general and administrative expenses, increasing working capital and for other general corporate purposes.

The securities to be issued under the offering have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities in the United States.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the use of proceeds of the offering. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and other documents we file from time to time with securities regulatory authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. We disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Nov 15, 2011

TSX Exchange Symbol: RVX

CALGARY, Nov. 15, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that a patent covering RVX-208 has been issued by the United States Patent and Trademark Office, adding to the portfolio of patents held by Resverlogix.

Patent US 8,053,440 contains composition of matter claims to the Company's clinical lead molecule, RVX-208, and structurally related compounds. Other claims related to RVX-208 are being pursued in other applications.  In addition, Resverlogix has received notices of allowance in other cases and are attending to formalities before these patents issue.  Corresponding applications in other jurisdictions are still pending.

"We are extremely pleased with the issuing of one of the key patents covering RVX-208. It further solidifies Resverlogix as a key player in the cardiovascular disease market and provides exclusive coverage for RVX-208 until 2030," stated Donald McCaffrey, President & Chief Executive Officer of Resverlogix.

Mr. McCaffrey continued, "Resverlogix devotes significant resources to ensure the protection of ideas and inventions related to the core areas of our business. Today, the Company's intellectual property portfolio covers compositions, methods and treatments for cardiovascular and inflammatory diseases, cancers and fibrotic diseases.  We believe that our know-how in these disease states will provide a significant competitive advantage. Resverlogix intends to continue to develop and protect our proprietary tools, methods, and trade secrets."

The Resverlogix patent portfolio currently consists of four issued patents:

1. Compounds for the prevention and treatment of cardiovascular disease, US 8,053,440.
2. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases, US 7,846,915.
3. Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices, NZ 566180.
4. Compounds and methods for down regulating the effects of TGF-beta, EP 1 648 520 B1.

It is the policy of Resverlogix to require employees, consultants, members of our Scientific and Clinical Advisory Boards, and other third parties in collaborative agreements to execute confidentiality agreements. Employee, consultant and contract research organization agreements specify that all inventions resulting from work performed using the Company's resources and work completed during employment/services performed are the Company's exclusive property, to the extent permitted by law.

About RVX-208

RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT).  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions.  Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts:

Nov 2, 2011

TSX Exchange Symbol: RVX

CALGARY, Nov. 2, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the commencement of dosing in ASSURE, a Phase 2b clinical trial led by the Cleveland Clinic.  ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial that will assess coronary atherosclerotic plaque changes in response to Resverlogix's lead drug RVX-208 using intravascular ultrasound (IVUS).  ASSURE will examine the early effects of RVX-208 induced ApoA-I production on atherosclerotic plaque regression in the setting of patients with coronary artery disease who have a low level of high-density lipoprotein cholesterol (HDL-C).  A total of 310 patients are expected to participate in ASSURE of which 77 will receive placebo and 233 will be given 100 mg twice daily of RVX-208.

An IVUS measurement will be taken prior to the first dose of RVX-208 and this will be repeated after 26 weeks of treatment. The primary trial endpoint will be IVUS measurement of a change in percent atheroma volume from baseline to 26 weeks. Secondary objectives for ASSURE are: (i) safety and tolerability of RVX-208 as reflected by adverse events, and (ii) effects of RVX-208 on HDL and non-HDL lipid parameters.

"We are very pleased to have dosed our first patient in the ASSURE clinical trial," stated Donald J. McCaffrey, President & Chief Executive Officer of Resverlogix. "Over the past two weeks we have seen substantial advancements in the enrollment progress for the ASSURE trial. Our initial two sites were activated in late September however most of our 53 regulatory approved sites have come on line in the past week and we expect the remaining 9 sites to be activated this month.  The enrollment procedure of ASSURE is to first screen the patients. Should they meet the protocol inclusion criteria, they are then entered into the trial and will be eligible for dosing two weeks after their screen acceptance.  We expect screening to proceed forward at a rapid pace, and once all patients have been enrolled we will update the market," McCaffrey added.

About RVX-208

RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT).  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT differentiates it from other HDL therapies. RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities, the conduct of the ASSURE trial and the potential role of RVX-208 in the treatment of atherosclerosis. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional assumptions and risk factors discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:

Sep 27, 2011

A New Clinical Trial Targeting High-Risk Cardiovascular Disease Patients

TSX Exchange Symbol: RVX

CALGARY, Sept. 27, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces today the commencement of dosing in SUSTAIN, a new Phase 2b clinical trial led by the Cleveland Clinic.  SUSTAIN will enroll 172 subjects with established cardiovascular disease (CVD) who continue to have a high-risk for recurrent CVD events.  All subjects in SUSTAIN will have a low level of high-density lipoprotein cholesterol (HDL-C) and are receiving standard of care therapy that includes up to 40 mg Atorvastatin or 20 mg Rosuvastatin.  SUSTAIN subjects will receive 200 mg/day of Resverlogix's lead compound RVX-208 or placebo in a 24-week, multi-center, double-blind, randomized, parallel group, placebo controlled clinical trial in order to assess lipid trends and safety.  In addition, other biomarkers of reverse cholesterol transport (RCT) will be examined.  The primary endpoint of SUSTAIN is the change in HDL-C from baseline after receiving RVX-208 for 24 weeks vs. placebo. Secondary endpoints include change in ApoA-I, LDL-C, non-HDL-C, apoB, TG and HDL subclasses.  The SUSTAIN trial will be conducted in South Africa.

The SUSTAIN trial is independent of ASSURE, a Phase 2b clinical study using intravascular ultrasound (IVUS) technology to assess atherosclerosis.

"We have learned several valuable lessons from the on-going analysis of our recently completed ASSERT Phase 2 trial," commented Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical Affairs.  "The ASSERT population was comprised of all patients who had stable CVD given standard of care therapy including statins.  The continued analysis of the ASSERT data revealed that subjects with low HDL who received targeted doses of Atorvastatin or Rosuvastatin seemed to benefit the most from the actions of RVX-208." 

The benefical actions of RVX-208 seen in ASSERT included significant rises in ApoA-I, the key protein in HDL, and HDL-C above baseline.  This knowledge guided Resverlogix in designing SUSTAIN to reconfirm the safety of RVX-208 and utilize its action in patients with low HDL. These patients, despite statin treatment, continue to have significant CVD events. This residual risk presents a huge unmet medical need and RVX-208 is well positioned to address this care gap.  According to the NHANES III study, it is estimated that nearly 35 million adults in the United States have low HDL.

"The data to be collected in SUSTAIN will further our understanding of how RVX-208 acts in a large number of patients with high residual CVD risk," said Donald J. McCaffrey, President & Chief Executive Officer of Resverlogix.  "When SUSTAIN and ASSURE are completed, we will have treated almost 1,000 patients worldwide with RVX-208. The launch of SUSTAIN reflects the confidence that we and others have in the potential for regressing atherosclerosis using RVX-208 to enhance RCT and thereby facilitate removal of cholesterol from atherosclerotic plaques to reduce CVD events." Mr. McCaffrey added, "it is important to note that SUSTAIN will not impact Resverlogix's annual budget because the previously planned Phase III tablet formulation program will be assigned lower priority thus allowing funds for SUSTAIN in the 2011/2012 budget.  We expect to have data from SUSTAIN next summer."

About RVX-208

RVX-208 is a novel small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. The use of this approach will enhance the functionality of HDL. ApoA-I is the major protein component of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called RCT.  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT makes it highly differentiated from all other HDL therapies. Thus RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis. 

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular and autoimmune diseases including; atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases, multiple sclerosis, rheumatoid arthritis, Crohn's and other autoimmune disorders . These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the most recent MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Sep 26, 2011

TSX Exchange Symbol: RVX

CALGARY, Sept. 26, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces today that study sites for the Phase 2b ASSURE clinical trial have now been activated.  This step opens the door for enrollment of patients in ASSURE (ApoA-l Synthesis Stimulation in Acute Coronary Syndrome), a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled clinical trial that will assess coronary atherosclerotic plaque changes in response to the Company's lead compound RVX-208 using intravascular ultrasound (IVUS).  ASSURE will examine the early effects of RVX-208 induced ApoA-I production on atherosclerotic plaque regression in the setting of patients with coronary artery disease who have a low level of high-density lipoprotein cholesterol (HDL-C). A total of 310 patients are expected to participate in ASSURE of which 77 will receive placebo and 233 will be given 100 mg given twice daily of RVX-208.

The primary endpoint will be IVUS measurement of a change in percent atheroma volume from baseline to 26 weeks. Secondary objectives for ASSURE are; (i) safety and tolerability of RVX-208 as reflected by adverse events, and (ii) effects of RVX-208 on HDL and non-HDL lipid parameters. Enrollment for ASSURE is expected to be completed by the end of the year.  The ASSURE study chair is Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine. The principal investigator for the trial is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at Cleveland Clinic.

"The ASSURE protocol arose from valuable knowledge gained in our Phase 2 ASSERT trial.  The ASSERT data clearly separates RVX-208 from its competitors by affecting three key biomarkers in reverse cholesterol transport (RCT).  In ASSERT, subjects given RVX-208 had; (i) a dose dependent and sustained increase in ApoA-l levels, (ii) a significant rise in HDL-C, especially alpha-1 particles or functional HDL, and (iii) a highly statistically significant increase in large HDL particles. These pronounced changes in the HDL profile arises from the initial RVX-208 induced increase in ApoA-I production and these changes in HDL point to enhanced RCT which in turn gives rise to the potential for atherosclerotic plaque regression," stated Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical Affairs. "Furthermore, we were encouraged by the dose-response relationship for lowering of hyper sensitive C-reactive protein (hs-CRP), also suggesting a beneficial effect on the artery wall," Dr. Johansson added.

"We are pleased to announce the initiation of the Phase 2b ASSURE trial; the foundation of which is based on critical knowledge from ASSERT.  In particular, the unique pathway by which RVX-208 raises 'functional' HDL in leading to atherosclerotic plaque regression, gives our lead compound a potential strategic advantage over other HDL therapies," stated Donald J. McCaffrey, President and Chief Executive Officer of Resverlogix.

About RVX-208
RVX-208 is a novel, orally active small molecule that stimulates endogenous ApoA-I production to trigger the synthesis of HDL. ApoA-I is the major protein component of HDL.  The use of this approach will enhance the functionality of HDL.  The main role of these particles is to act as the body's natural defense system against atherosclerosis by mediating a normal physiologic process called reverse cholesterol transport (RCT).  This pathway enables cholesterol, including that within atherosclerotic plaques of vessel walls, to be transported to the liver for further processing and elimination from the body.  Enhanced RCT clearance of cholesterol from vessel walls should reduce or prevent atherosclerosis. The ability of RVX-208 to increase ApoA-I production and thereby augment RCT makes it highly differentiated from all other HDL therapies. Thus RVX-208 is positioned to be one of the most promising drugs in development for the treatment of atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular and autoimmune diseases including; atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases, multiple sclerosis, rheumatoid arthritis, Crohn's and other autoimmune disorders . These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the most recent MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Sep 1, 2011

TSX Exchange Symbol: RVX

CALGARY, Sept. 1, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX: RVX) announced today that two abstracts on the analysis of the ASSERT trial were presented at the European Society of Cardiology (ESC) Congress 2011 in Paris, France. The abstracts were co-authored by Resverlogix Senior Scientists and Clinical Steering Committee members: S.J. Nicholls, A. Gordon, J. Johansson, C.M. Ballantyne, J.J.P. Kastelein, N.C.W. Wong, M. Borgman, K. Wolski, and S.E. Nissen.

The Phase 2 ASSERT clinical trial's lead compound RVX-208 is an orally active small molecule that raises Apolipoprotein A-I (ApoA-I) production, the key protein in high-density lipoprotein (HDL) known as the 'good cholesterol'.  Data gathered in the ASSERT trial showed that RVX-208 enhanced biomarkers of reverse cholesterol transport (RCT), thus reflecting robust cholesterol clearance from arterial wall plaques via this metabolic pathway.  This action of RVX-208 is unique and when added to new knowledge of the target protein bound by the compound, it indicates that RVX-208 is clearly different from all other drugs in the sphere, including cholesteryl ester transfer protein (CETP) inhibitors.

The current analysis of the ASSERT trial yielded new findings summarized in the presentation titled: "Increasing Circulating Concentration of all HDL Particle Subclasses in Hyper-Responders: Insights from the ASSERT Study to ApoA-I Induction." Abstract link: http://spo.escardio.org/AbstractDetails.aspx?id=100468&eevtid=48

Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical Affairs, highlighted the significance of this observation noting that, "enhanced RCT is a highly sought after goal in drug development because it gives us a chance to regress atherosclerosis within the vessel wall.  This new data helped identify a large high-risk patient population with low HDL levels whereby significant benefit may be gained from the actions of RVX-208."

The second ESC presentation titled: "Apolipoprotein A-I Induction Therapy is Associated with Reduction in Inflammatory Biomarkers: Potential Implications for Functionality of High-Density Lipoproteins," demonstrated the potential of RVX-208 in lowering CRP, a recognized biomarker of cardiovascular risk and inflammation.  Abstract link: http://spo.escardio.org/AbstractDetails.aspx?id=97764&eevtid=48

"These new observations are valuable in advancing our Phase 2b ASSURE clinical trial of RVX-208 to examine atherosclerosis regression using intravascular ultrasound (IVUS) and biomarkers of RCT for 26 weeks in patients with Coronary Artery Disease," said Donald J. McCaffrey, President & Chief Executive Officer of Resverlogix.  "This new data in the two ESC presentations has not only enriched our understanding of how RVX-208 can augment RCT, and thus enable regression of atherosclerosis, but also the expanded therapeutic potential of RVX-208 in alternate indications."

About RVX-208

RVX-208 is a novel small molecule therapeutic that facilitates endogenous ApoA-I production.  It is positioned to be one of the most promising emerging drugs in development for the treatment of atherosclerosis. To the Company's knowledge, RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment RCT and ultimately plaque regression. RCT is a pathway by which cholesterol that has accumulated within the arterial wall can be transported to the liver for excretion, thus reducing or preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease, and Autoimmune diseases. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular and autoimmune diseases including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Jun 28, 2011

TSX Exchange Symbol: RVX

CALGARY, June 28, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces today the presentation of additional new findings arising from analysis of data gathered in the Phase 2 ASSERT trial at the annual meeting of the European Atherosclerosis Society (EAS) in Gothenburg, Sweden.  The EAS is a prestigious meeting that brings together both clinicians and scientists to share new knowledge in the battle against atherosclerosis.  At the EAS, there were two presentations co-authored by prominent scientists from Resverlogix's Clinical Steering Committee.

Resverlogix's previous studies have demonstrated RVX-208 to be an orally active small molecules that raises Apolipoprotein A-I (apoA-I) production.  In the recently completed ASSERT trial, Resverlogix illustrated that RVX-208 enhanced biomarkers of reverse cholesterol transport (RCT) in keeping with its unique mechanism of action.  The on-going analysis of the ASSERT data yielded new findings that formed the substance of an EAS presentation entitled "Anti-Inflammatory Effects of a Novel Inducer of Apolipoprotein A-I Synthesis: Insights from the ASSERT Study" showing the potential role of RVX-208 in lowering hsCRP, a well-known biomarker of inflammation which is an important process in the pathogenesis of atherosclerosis.

Dr. Jan Johansson, Resverlogix's Senior Vice President of Medical Affairs, commented, "This observation is intriguing because it begins to shine a light on the actions of RVX-208 that may extend beyond the production of apoA-I."

A second EAS presentation entitled "Increasing Circulating Concentration of All HDL Particle Subclasses in Hyper-Responders to Apolipoprotein A-I Induction: Insights from the ASSERT Study" emphasized a unique mechanism by which RVX-208 augments RCT, a pathway for clearing cholesterol from the body.  Enhanced activity of this pathway is believed to not only stabilize, but possibly regress, atherosclerosis within coronary vessels.  Based on this information, Dr. Johansson stated, "We now know the characteristics of a large high-risk patient population in whom significant benefit may be gained from the actions of RVX-208."

Mr. Don McCaffrey, President & CEO of Resverlogix, continued, "Adding these new learnings to other observations from ASSERT underscores the rationale for ASSURE, a Phase 2b trial of RVX-208 in which atherosclerosis regression as determined by intravascular ultrasound (IVUS) and biomarkers of reverse cholesterol transport will be the measured over a 26 week period. We will continue to learn from these and additional findings from ASSERT so that we may apply this knowledge in the design of clinical trials which will target patient populations who have the greatest need."

About RVX-208
RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. Apolipoprotein A-I (apoA-I), the main component of high-density lipoprotein (HDL), represents the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport (RCT), i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for processing. To the Company's knowledge RVX-208 is the only orally active small molecule that selectively stimulates apoA-I production to increase levels of HDL. The use of this approach will enhance HDL functionality in mediating RCT, a pathway by which cholesterol that has accumulated in atheroma within the arterial wall can be transported to the liver for excretion, thus reducing or preventing atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance apoA-1 production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular diseases including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Jun 27, 2011

TSX Exchange Symbol: RVX

CALGARY, June 27, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that key scientific data has been presented in a poster presentation highlighting the novel features of RVX-297, at the 10th World Congress on Inflammation, in Paris, France (poster number P-296, June 27 at 1 pm). The presentation is entitled "An Orally Bioavailable Small Molecule RVX-297 Significantly Decreases Clinical Signs In A Mouse Model Of Multiple Sclerosis."

"RVX-297 is a representative molecule from our autoimmune program, which was established to expand upon important discoveries made during our investigative research on pharmacological approaches for controlling the inflammatory components of atherosclerosis," stated Don McCaffrey, President & CEO of Resverlogix.

Mr. McCaffrey continued, "Autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis and Crohn's disease currently represent a significant unmet medical need globally. The novel, orally bioavailable small molecule drugs under development by Resverlogix possess unique immunopharmacological properties and have the potential to compete effectively against expensive protein-based therapeutics which currently dominate the autoimmune market."

The poster presentation includes data demonstrating that RVX-297 both prevents onset of and treats established disease in murine experimental autoimmune encephalomyelitis (EAE), a well-accepted animal model of multiple sclerosis (MS).  The effects in the treatment model included a dramatic reduction in clinical signs, histopathological evidence of disease, and expression of inflammatory biomarkers of disease. Dr. Gregory. S. Wagner, Sr. Vice President of R&D, further stated "RVX-297 also blocked the production of the cytokines IL-6 and IL-17, which are believed to be critical mediators in development of the autoimmune response in this model. Resverlogix is very excited about these results with RVX-297 because blocking IL-6 or IL-17 has shown evidence of clinical benefit in a number of autoimmune indications, suggesting that this new class of molecules, which combine the two activities in an oral formulation, may be effective in a range of autoimmune diseases."

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1 production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's research in autoimmune disorders represents a second important therapeutic research area of high unmet medical need. These therapies are targeted to address the increasing incidence of autoimmune disorders such as multiple sclerosis (MS) and other inflammatory disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular and autoimmune diseases including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases, multiple sclerosis, rheumatoid arthritis, Crohn's and other autoimmune disorders that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Jun 23, 2011

CALGARY, June 23, 2011 /CNW/ - Mr. Don McCaffrey, President and CEO of Resverlogix Corp. (TSX:RVX) is pleased to announce today the addition of Professor H. Bryan Brewer to Resverlogix's Clinical Steering Committee.  Professor Brewer, a cardiologist, is currently the Director of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, Washington Hospital Center, Washington, D.C., USA.  Professor Brewer was the former Chief of the Molecular Disease Branch at the National Institute of Health, Bethesda, MD, USA and is a leader and pioneer in the field of high density lipoprotein (HDL) research.  His seminal observations led to the cloning of the Apolipoprotein A-I (ApoA-I) mRNA and the gene.  The availability of the ApoA-I mRNA and gene enabled clinicians and scientists to understand the role of ApoA-I protein in reverse cholesterol transport (RCT) and atherosclerosis protection. 

"Professor Brewer is one of the most well respected pioneers in the field of HDL biology.  He has extensive industry expertise having served as a consultant to major pharmaceutical companies including Abbott, Lilly, Merck, Pfizer, Roche, Sanofi-Aventis and Schering-Plough.  These skills will enhance the activities of our Clinical Steering Committee which is instrumental in the design and conduct of Resverlogix's human clinical trials relating to its lead compound RVX-208," said Mr. McCaffrey. 

Dr. Jan Johansson, Senior Vice President of Medical Affairs of Resverlogix stated, "Dr. Brewer's joining our Clinical Steering Committee further validates RVX-208's unique position in the critically important atherosclerosis market. Our highly differentiated mechanism in HDL biology, the raising of ApoA-I production and enhancement of RCT biomarkers, is seen by many as the most logical approach to harness the benefits of RCT and provide efficient reduction of atherosclerosis burden from coronary arteries. If our lead drug RVX-208 can facilitate this type of effect in high risk CVD patients in only 26 weeks it will be positioned as a new breakthrough treatment for millions of patients around the world".

The Company has gained valuable insight from the recently completed Phase 2 ASSERT trial. The important knowledge from ASSERT enabled us to identify and target high-risk patients for the next trial of RVX-208 called ASSURE.  The Phase 2b ASSURE trial will target high-risk CVD patients who have low HDL.  The AHA 2010 report states that more than 35 million American adults have low HDL. ASSURE is the first Phase 2b clinical trial lasting 26 weeks to examine a novel small molecule, RVX-208, that enhances ApoA-I production in CVD patients with low HDL.  In ASSURE, intravascular ultrasound (IVUS) will be used to measure changes in coronary atherosclerosis as the primary endpoint, while measures of RCT biomarkers will serve as secondary endpoints.

About RVX-208
RVX-208, a small molecule therapeutic that stimulates endogenous ApoA-I production, is positioned to be one of the emerging drugs that holds most promise in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only orally active small molecule that selectively stimulates ApoA-I production to increase levels of HDL.  The use of this approach will enhance HDL functionality in mediating reverse cholesterol transport (RCT). RCT is a pathway by which cholesterol that has accumulated in atherosclerotic plaques within the arterial wall can be transported to the liver for excretion, thus stabilizing, reducing or preventing atherosclerosis disease conditions.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Jun 14, 2011

/NOT FOR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWSWIRE SERVICES./

TSX Symbol: RVX

CALGARY, June 14, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has closed its previously announced prospectus offering of 7 million units (the "Units") at a price of CDN $1.80 per Unit for gross proceeds of $12.6 million (the "Offering"). Each Unit was comprised of one common share of the Company and one-half of a common share purchase warrant. Each full warrant is exercisable at a price of CDN $2.25 for a period of five years. The offering was co-led by Bloom Burton & Co. and Canaccord Genuity Corp. with Wedbush PacGrow Life Sciences acting as financial advisor in certain jurisdictions outside Canada where it is qualified to carry on business.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: Don@resverlogix.com

Jun 13, 2011

TSX Exchange Symbol: RVX

CALGARY, June 13, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that the Company has completed its chronic repeated-dose toxicology studies on its lead compound, RVX-208, indicated for the reduction and prevention of atherosclerosis.  These chronic toxicology studies support the initiation of its longer duration, Phase IIb, clinical trial ASSURE. As a first-in-class compound, RVX-208 underwent six and twelve month testing in rodents and non-rodents, respectively, and the analysis, results and reporting of these studies to the appropriate regulatory authorities, have been completed.

With the safety studies complete, RVX-208 can now advance into trials of more than three months duration. The Phase IIb ASSURE trial, in which Intra Vascular Ultra Sound (IVUS) technology will be used to determine coronary arterial plaque regression, will have a treatment duration of six months.  The IVUS measurement will be used as the trial's primary endpoint.

Results from the recently completed ASSERT trial strongly demonstrate that RVX-208 is efficacious in elevating new production of ApoA-1, the key protein in 'good cholesterol', HDL cholesterol and HDL Alpha1 sub particles. None of these reverse cholesterol transport biomarkers appear to have reached their plateaus at the completion of that 12 week trial. As a result, Resverlogix was required by the FDA rules to complete the safety studies in order to progress to a six month human clinical study.

Resverlogix has identified more than 60 clinical sites in eight countries that will participate in the ASSURE trial study.  The Cleveland Clinic will serve as the trial co-manager and coordinate all data management and readouts of the primary endpoint. Countries with secured trial sites are located in both Europe and South America. With the completion of these chronic repeated-dose toxicology studies, Resverlogix has commenced the required national approval filings.  Upon completion of regulatory filings in each specific country, Resverlogix will then commence enrollment and dosing procedures.

"We are pleased to have completed and filed the data associated with the repeated-dose toxicology studies and that the trial is progressing according to timelines that we had previously discussed," said Donald J. McCaffrey, Resverlogix President and Chief Executive Officer.

The ASSURE trial is a placebo-controlled, double-blind intervention trial designed by Resverlogix in conjunction with the Cleveland Clinic and the Clinical Steering Committee, consisting of Drs. Steve Nissen, John Kastelein, Christie Ballantyne,  Phil Barter, and  principal investigator Dr. Stephen Nicholls. The trial patient population will be selected from patients referred for coronary angiography who meet selected angiographic criteria. Approximately 310 patients will participate, of which 77 will receive placebo and 233 will receive RVX-208 treatment.  Clinical trial information will be posted on www.Clinicaltrials.gov prior to first dosing.

Webcast Announcement:  In additional news Resverlogix Corp. will host a live Analyst teleconference and webcast on Tuesday, June 21^st at 11:00am Mountain time.  The purpose of the teleconference is to provide a market update from management regarding clinical trial developments. The dial-in numbers for this event will be 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix' website and can be accessed from the following address
http://services.choruscall.com/links/resverlogix110613.html .

The webcast will be available on the Resverlogix website for a period of 45 days after the event.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-1 production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus reducing or preventing atherosclerosis.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1 production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease, the conduct of the ASSURE trial and statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Jun 3, 2011

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES./

TSX Symbol: RVX

CALGARY, June 3, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that Bloom Burton & Co. and Canaccord Genuity Corp. (the "Agents"), along with Wedbush PacGrow Life Sciences acting as financial advisor in certain jurisdictions outside Canada where it is qualified to carry on business, have carried out the Overnight Marketed Offering announced yesterday and confirmed $12.6 million in demand for equity units, representing 7 million units at a price of $1.80, whereby each unit includes one common share and a one-half (1/2) of a common share purchase warrant. Each warrant is exercisable at a price of $2.25 for a period of 5 years from the closing of the offering. The offering is to be effected in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus dated April 20, 2010. Prior to the offering, Resverlogix had 52,277,907 common shares issued and outstanding.

This transaction is scheduled to close on or about June 14, 2011, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company's securities in the United States.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financingsand statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-690-8887
Email: Don@resverlogix.com

Jun 2, 2011

/This press release is not for dissemination in the United States or through US newswire services./

TSX Symbol: RVX

CALGARY, June 2, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has undertaken an overnight marketed offering of units, each unit being comprised of one common share and a portion of a common share purchase warrant. The offering is being co-led by Bloom Burton & Co. and Canaccord Genuity Corp. with Wedbush PacGrow Life Sciences acting as financial advisor in certain jurisdictions outside Canada where it is qualified to carry on business. The offering is to be effected in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus dated April 20, 2010. Prior to the offering, Resverlogix had 52,277,907 common shares issued and outstanding. The number of units to be distributed, the price of each unit and the exercise price of each whole common share purchase warrant will be determined in context of the market.

This transaction is scheduled to close on or about June 14, 2011, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company's securities in the United States.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings and statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-690-8887
Email: Don@resverlogix.com

Jan 25, 2011

ASSERT study shows increased transport of Amyloid Beta 40

TSX Exchange Symbol: RVX

CALGARY, Jan. 25 /CNW/ - Resverlogix announced today that its lead drug RVX-208, a first in class ApoA-I production drug, illustrated positive effects on an important cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta 40 (Aβ₄₀). This analysis was performed based on increasing evidence in the literature that the transport of potentially harmful Aβ₄₀ from the brain to the general circulatory system may be beneficial.

Several population studies have indicated that high HDL cholesterol is associated with protection from developing Alzheimer's Disease. It has also been shown that low plasma Aβ₄₀ is a risk factor for developing Alzheimer's Disease in older patients. Since the Alzheimer's Disease biomarker Aβ₄₀ bind to ApoA-I it has been hypothesized that increasing ApoA-I would transport Aβ₄₀ out of the brain thereby decreasing the Aβ₄₀ load in the brain, in effect having possible disease modifying effect.

To assess potential for treatment effects by RVX-208 on Alzheimer's Disease, plasma Aβ₄₀ was analyzed before and after 12 weeks treatment in a stable coronary artery disease population, i.e. the ASSERT population of 299 patients.

In the quartile with the lowest plasma Aβ₄₀ at baseline, which is known to be at greater risk for developing Alzheimer's Disease, at a dose of 150 mg, b.i.d., a highly significant 34.8 pg/mL change from baseline (p=0.0013) and 13.4% change compared to placebo was observed. The data further supports previous Phase I trial data and the hypothesis that RVX-208 treatment can also augment Aβ₄₀ transport from the brain.

Dr. Jan Johansson Senior Vice President of Medical Affairs stated, "We have been building upon a hypothesis that increased Aβ₄₀ seen in plasma illustrates movement out of the brain. We believe the augmented ApoA-I production by RVX-208, functional HDL and enhanced reverse cholesterol transport, could be transporting potentially harmful Aβ₄₀ from the brain to plasma. This is a very important new area of neurovascular biology that we intend to pursue."

"These repeated findings will help continue to drive our efforts to further understand the complex relationship between lipoproteins, amyloid beta and the devastating disease of Alzheimer's. Further analysis and planning will take place prior to determining the next steps, however, as this drug has already passed Phase I, of the FDA review process, a future trial would likely  commence as a Phase II program in Alzheimer's Disease patients," added Dr. Johansson.

Emerging evidence and data is accumulating for a protective effect of good HDL cholesterol against Alzheimer's Disease. Key findings from large epidemiology studies such as the Harvard Women's Study, the Honolulu Aging Study, the White Hall 2 study and the Manhattan Cognitive Study continue to build the relationship between increased HDL, ApoA-I and improved cognitive function and Alzheimer's outcomes.

About RVX-208
RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for processing. Analysis of cognitive biomarkers such as Amyloid Beta 40 (Aβ₄₀) in conjunction with lipid transport markers may also provide new research and development opportunities for RVX-208 in important disease areas such as Alzheimer's Disease. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT) and Aβ₄₀ transport.

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as HDL and ApoA-I. A critical part of RCT is cholesterol efflux, in which accumulated cholesterol is removed from macrophages.

The American Heart Association estimates that almost 80 million American Adults have one or more types of cardiovascular disease. CVD remains the number one killer of developed nations. Nearly 2400 Americans die each day from cardiovascular disease.

About ASSERT Trial
The ASSERT study evaluated early biochemical changes in association with increasing doses of an apoA-I inducer (RVX-208 100-300 mg daily) for 12 weeks in statin-treated patients with stable coronary artery disease.

About Vascular Dementia Multi-infarct dementia, also known as vascular dementia, is the second most common form of dementia after Alzheimer's Disease in older adults. Early detection and accurate diagnosis are important, as vascular dementia is at least partially preventable. Vascular dementia is the second most common cause of dementia in the United States and Europe in the elderly, but it is the most common form in some parts of Asia. The prevalence of the illness is 1.5% in Western countries and approximately 2.2% in Japan. It accounts for 50% of all dementias in Japan, 20% to 40% in Europe and 15% in Latin America. The incidence of dementia is 9 times higher in patients who have had a stroke than in controls. 25% of stroke patients develop new-onset dementia within 1 year of their stroke. The relative risk of incident dementia is 5.5% within 4 years of suffering a stroke.

About Alzheimer's Disease
Every 71 seconds, someone in America develops Alzheimer's Disease and it is estimated that by mid-century, someone will develop Alzheimer's every 33 seconds. Neurodegenerative diseases such as Alzheimer's are one of the most debilitating in the developed world with an estimated prevalence in the United States alone to grow to 15 million people by 2050. In a report commissioned by the Alzheimer's Association, caregiver costs in the United States are estimated at US$36.5 billion which includes loss of productivity, absenteeism and worker replacement. In addition it is also estimated that one-half to two-thirds of the cost of AD care stems from unpaid caregivers (often family members), who spend 16-35 hours per week looking after a person with AD. These figures underscore the importance of developing new therapies to aide in the socioeconomic burden of AD.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the October 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release. 

Website:  www.resverlogix.com

Dec 13, 2010

Cleveland Clinic Researchers and the Resverlogix Clinical Steering Committee Announce the ASSURE Trial Advancement

TSX Exchange Symbol: RVX

CALGARY, Dec. 13 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX)  announces that Dr. Eldon R. Smith OC, MD, FRCPC, FCAHS, FAHA, FIACS has been appointed to the Company's Board of Directors. The Board remains at 6 members.

From 1992 to 1997, Dr. Smith was Dean of the Faculty of Medicine at the University of Calgary. From 1997 until 2010, he has been Editor-in-Chief of the Canadian Journal of Cardiology. Dr. Smith's research interests include circulatory mechanics, exercise physiology and echocardiography. He has published more than 250 papers and book chapters and has been a contributor to many national and international organizations; he has been President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges and Vice President of the Inter-American Society of Cardiology. He has served on a number of public boards including the Alberta Heritage Foundation for Medical Research, the Alberta Health Professions Advisory Board, and the Premier's Advisory Council on Health in Alberta. He founded and served as President and Director of the Peter Lougheed Medical Research Foundation, a national initiative to support excellence in health research in Canada. He is chair of the Advisory Board of the Libin Cardiovascular Institute of Alberta and from 2006 to 2010 he was appointed by the Federal Government to chair the development of a National Strategy for Cardiovascular Health and Disease.

Resverlogix's Board of Directors remains at 6 members as Dr. William Cochrane will be stepping down from the Board effective today. Dr. Cochrane has been on the Board since its inception and has been a very important contributor to the growth and development of Resverlogix. The Board expresses its gratitude to Dr. Cochrane for his years of contributions. Current Board member, Dr. Peter Johann, has been appointed as Dr. Cochrane's replacement as Chairman of the Board. Dr. Johann is a Managing General Partner of NGN Capital. He was formerly the Division Head of Corporate Development for Boehringer Ingelheim and was Global Business Leader at F. Hoffman-La Roche.

Also announced today, Cleveland Clinic Researchers in combination with Resverlogix and the Clinical Steering Committee will advance the ASSURE IVUS study with unanimous approval. The committee consists of Dr. Steven Nissen, Dr. John Kastelein, Dr. Christie Ballantyne, Dr. Phil Barter and Dr. Stephen Nicholls.

In the upcoming Phase IIb multi-center, double-blinded, randomized "ApoA-I Synthesis Stimulation in Coronary Patients" (ASSURE) trial, researchers will test approximately 350 patients using a placebo-control arm for the assessment of coronary plaque changes with RVX-208 over a six month period, as determined by intravascular ultrasound.

"Attempts at plaque-reducing medications have largely focused on increasing HDL cholesterol levels because of HDL's ability to remove plaque and prevent plaque formation," said Stephen J. Nicholls, M.B.B.S., Ph.D., Principal Investigator of the upcoming ASSURE trial and Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research. "However, enhancing ApoA-I synthesis would represent a significant paradigm change, in which the target is functional quality - rather than quantity - of HDL.

The six month ASSURE trial should benefit from these key changes based from the fact that ApoA-I, HDL and large HDL particles continued to increase throughout the ASSERT trial suggesting that peak pharmacologic effects had not yet been fully achieved at three months. The safety profile of the drug also suggested it was well within acceptable limits to allow for the advancement of the ASSURE trial. No evidence of liver damage was seen in the ASSERT trial thus allowing the ASSURE trial to move forward. Trial timing and enrollment details will be confirmed in H1, 2011 and further trial design updates and progress will be posted on www.Clinicaltrials.gov.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Nov 29, 2010

Patent filing is based on synergistic findings suggesting enhanced plaque management with RVX-208 in combination with statins

TSX Exchange Symbol: RVX

CALGARY, Nov. 29 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed ASSERT Phase 2 clinical trial. A new patent application has been filed for novel dosing combinations of RVX-208 and leading statin therapeutics. The patent was filed based on the results demonstrated in the ASSERT trial. Resverlogix' findings in a post-hoc analysis of ASSERT data revealed that RVX-208 in certain doses along with leading statin drugs markedly improved not only ApoA-I production, HDL and large HDL particles, but also important aspects of LDL and ApoB particles.  All of these positive changes took place in patients on the best standard of care currently available.

"The bonus finding of ApoB and LDL lowering while on statins and not in placebo's was a surprise finding and is useful in selecting the best statin co-medications going forward for maximum treatment effect. The effects seem most efficacious in the leading stains, being Pfizer's Lipitor and AstraZeneca's Crestor. Resverlogix will further delineate this positive synergistic effect from a mechanistic point of view," stated Dr. Jan Johansson, Senior Vice President of Medical Affairs of Resverlogix. "To have these additional findings of unexpected enhanced statin performance, in combination with RVX-208, offers us an added approach to providing an array of new therapies to reduce atherosclerosis and coronary vascular disease," Dr. Johansson added.

"ASSERT, as it was designed to do, taught us several key findings," stated Kenneth Lebioda, Senior Vice President Business & Corporate Development of Resverlogix. "We now understand with greater clarity that RVX-208 works better in high risk patients with low HDL and that certain doses have far greater effect in promoting markers of reverse cholesterol transport (RCT). After careful analysis of all the data we also found that when RVX-208 is used with certain statins we see significant reductions in liver signals such as ALTs while still maintaining very good efficacy. These key findings have helped us immensely in designing a more powerful, accurate and targeted ASSURE Phase 2b trial.  In terms of business development this new patent filing greatly expands the scope of our commercial program," Lebioda added.  

Resverlogix to Host Webcast Today

Resverlogix Corp. will host a live teleconference and webcast on Monday, November 29, 2010 at 11:00 am Mountain time. The purpose of the teleconference is to provide a market update from management. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix101129.html.

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Nov 25, 2010

TSX Exchange Symbol: RVX

CALGARY, Nov. 25 /CNW/ - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Monday, November 29, 2010 at 11:00 am Mountain time. The purpose of the teleconference is to provide a market update from management.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix101129.html.

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This media alert may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this media alert are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Nov 17, 2010

A second AHA presentation includes mouse model data showing plaque reduction.

TSX Exchange Symbol: RVX

CHICAGO, Nov. 17 /CNW/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX)  announces its top line results of the ASSERT Phase 2 clinical trial which will be highlighted at the prestigious American Heart Association Scientific Sessions 2010 Late Breaking Clinical Trial session, by principal investigator Dr. Stephen Nicholls of the Cleveland Clinic. The top line ASSERT trial data was designed to answer questions about how to best proceed with future trial designs for Resverlogix' lead oral small molecule drug RVX-208.

The ASSERT trial data demonstrated that the three key biomarkers in the reverse cholesterol transport (RCT) process showed dose dependant and consistent improvement. The trial showed dose dependent increases in ApoA-l, statistically significant increases in HDL cholesterol including alpha1 particles or functional HDL, and highly statistically significant increases in large HDL particles. RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus reducing and/or preventing atherosclerosis.

In the high dose, ApoA-I achieved a 5.6% increase with a statistical value of p=0.06. The overall ApoA-I biomarker showed a dose trending statistical significance of p=0.035. Data presented also showed that the ApoA-I and other HDL particles continued to be increasing at the end of the 12 week study. Both the 8.3% HDL cholesterol increase and the 21.1% large particle HDL increase were highly statistically significant, p<0.01 and p<0.001 respectively. These pronounced HDL related increases via ApoA-I production are important as they take place later in the RCT chain of events and strongly indicate plaque regression potential.

"These are very encouraging early findings which suggest the drug (RVX-208) is working in the established patient population that it was designed for, being patients with advanced coronary disease,"  said Dr. Stephen Nicholls, MBBS, PhD, Medical Director of Intravascular Ultrasound and Angiography Core Laboratories at Cleveland Clinic and Clinical Director of the Cleveland Clinic Center for Cardiovascular Diagnostics and Prevention.

Donald McCaffrey, President and Chief Executive Officer of Resverlogix commented, "The study largely replicates findings previously seen in our earlier 28 day trial, more importantly these findings are now being shown in patients with coronary artery disease on optimal  standard of care. The positive changes seen in this trial represent advancement over the current best standard of care available in the USA. We are now well positioned to advance RVX-208 to the next clinical trial having witnessed the substantial and consistent elevation of HDL by ApoA-I production; which strongly indicates that RVX-208 should remove unwanted plaque from the arterial wall which is our main goal."

Resverlogix Senior Vice President of Medical Affairs Dr. Jan Johansson stated, "In patients who received the newer class of statins and had baseline HDL below 45mg/dL, an important high-risk subpopulation, the middle dose of 200 mg saw the most pronounced increases of 12% in ApoA-I (p<0.002), 21% in HDL cholesterol (p<0.015) and 32% in large particle HDL (p<0.018). We are delighted by these results and now have a much better understanding of what doses to use and what patient population to target moving forward in our ASSURE Phase 2b trial." 

An additional presentation at the AHA meeting was given by Dr. Norman Wong, Chief Scientific Officer of Resverlogix, containing new data detailing the effects of RVX-208 in vivo. The presentation was titled "RVX-208: An Orally Administrated Small Molecule Reduces Atherosclerosis in ApoE Null Mouse and Raises ApoA-I/HDL in Humans". In the ApoE null mice model of atherosclerosis, the oral administration of RVX-208 reduced aortic plaques in two separate models.  The presented model showed plaque reductions of up to 41%.

Resverlogix to Host Webcast on ASSERT Phase 2 Trial Results - change in time
Resverlogix Corp. will host a live teleconference and webcast today at 2:15 pm Central/1:15 pm Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 2 clinical trial (ASSERT) for RVX-208. The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix101117.html.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at . Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release. www.sedar.com

%SEDAR: 00019253E

Nov 15, 2010

TSX Exchange Symbol: RVX

CHICAGO and CALGARY, Nov. 15 /CNW/ - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Wednesday, November 17, 2010 at 1:30 pm Central/12:30 pm Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 2 clinical trial (ASSERT) for RVX-208, an oral small molecule in development to treat atherosclerosis and cardiovascular disease.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix101117.html

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This media alert may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this media alert are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Sep 30, 2010

TSX Exchange Symbol: RVX

CALGARY, Sept. 30 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that Mr. Kenneth Zuerblis has been appointed to the Company's Board of Directors. Recently Mr. Zuerblis served as the Chief Financial Officer and Senior Vice President of ImClone Systems Inc., prior to its acquisition by Eli Lilly.

"I was initially attracted to Resverlogix because of RVX-208, its novel atherosclerosis drug, which is a very exciting mid-stage therapeutic gaining worldwide scientific acceptance. Resverlogix is also developing a pipeline of novel therapeutics in several disease categories that have significant unmet medical needs. I look forward to this opportunity to work with members of the Board of Directors and management as we develop the full potential of the Company's product candidates," Mr. Zuerblis commented.

Donald J. McCaffrey, President & CEO of Resverlogix, stated, "Ken is a seasoned veteran in the biotechnology industry with a proven track record of running complex commercial and research organizations and we are delighted that he has joined our Board of Directors." In an effort to maintain a Board of Director level at six people Mr. Wayne Chiu will be stepping down from the Board effective today. Wayne has been on the Board since its inception and has been an important contributor to the growth and development of Resverlogix. The Board expresses its thankfulness to Wayne for his years of contributions.

Kenneth J. Zuerblis biography

Mr. Zuerblis previously served as Chief Financial Officer and Senior Vice President of ImClone Systems, a biopharmaceutical company developing biologic medicines in the area of oncology, from 2008 through 2009 at which time he helped lead the sale of the company to Eli Lilly for $6.6 billion USD. Prior to joining ImClone, Mr. Zuerblis served as Chief Financial Officer of Enzon Pharmaceuticals Inc. from 1994 through 2005 and Corporate Controller from 1991 through 1994. He began his career at KPMG, LLP, in 1982, ultimately serving as Senior Manager prior to his departure in 1991. Mr. Zuerblis previously served as a member of the Board of Directors of XTL Biopharmaceuticals, Ltd., and is a member of the Board of Directors of Immunomedics and the New Jersey Technology Council. He received a BS in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 403-254-9252,
Email: Theresa@resverlogix.com;

US Institutional Investors:
Susan Noonan, Managing Partner,
S.A. Noonan Communications, LLC,
Phone: 212-966-3650,
Email: Susan@sanoonan.com

Sep 10, 2010

Increased number of patients and the focus is on patients with greatest medical need

TSX Exchange Symbol: RVX

CALGARY, Sept. 10 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.

    <<
    Key changes to this clinical trial include:
    -  Raising the number of patients to be recruited from 120 to over 230.
    -  All patients will now undergo an intravascular ultrasound (IVUS)
       assessment versus the previously planned 60 patients.
    -  Trial sites increase from 20 to approximately 45.
    -  Clinical trials will be conducted in multiple countries to accelerate
       recruitment.
    -  The study will include patients with low HDL.
    -  Primary endpoint is now plaque regression.
    >>

Donald J. McCaffrey, President & CEO of Resverlogix noted, "The most important take away message is that by moving the end point to atherosclerosis regression this will provide a more robust proof of concept. Achieving plaque regression could potentially reduce the development time for RVX-208 by two years."

The planned trial is currently a three month study and dosing is expected to start in 2010. Any changes to the trial will be updated on www.clinicaltrials.gov.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-1 production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 403-254-9252,
Email: Theresa@resverlogix.com;

US Institutional Investors:
Susan Noonan, Managing Partner,
S.A. Noonan Communications, LLC,
Phone: 212-966-3650,
Email: Susan@sanoonan.com

Aug 23, 2010

TSX Exchange Symbol: RVX

CALGARY, Aug. 23 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today that it has surpassed an important business marker for the Company - historical trading of Resverlogix's shares on the Toronto Stock Exchange has now passed the $1 billion dollar mark on the TSX exchange.

Donald J. McCaffrey, President & CEO of Resverlogix stated, "This accomplishment is worthwhile highlighting to shareholders as it once again illustrates our ability to maintain a strong position in the Canadian Life Sciences sector. By crossing the $1 billion trading threshold Resverlogix becomes one of only a handful of the 61 life sciences companies, currently trading on the TSX, which have surpassed this lofty level." McCaffrey noted "This accomplishment clearly shows a high level of liquidity for Resverlogix stock and interest in our atherosclerosis technology. The importance of liquidity is that it is a key investment factor for larger institutions when they are considering long term investments in early stage Life Science companies."

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the July 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 403-254-9252,
Email: Theresa@resverlogix.com;

US Institutional Investors:
Susan Noonan, Managing Partner,
S.A. Noonan Communications, LLC,
Phone: 212-966-3650,
Email: Susan@sanoonan.com

Jun 22, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES/

TSX Symbol: RVX

CALGARY, June 22 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has closed its previously announced prospectus offering of 3.1 million units (the "Units") at a price of CDN $3.23 per Unit for gross proceeds of CDN $10 million. Each Unit was comprised of one common share of the Company and 0.4 of a common share purchase warrant. Each full warrant is exercisable at a price of CDN $4.00 for a period of four years.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 403-254-9252,
Email: Theresa@resverlogix.com;

Jun 22, 2010

New data from Phase 1b/2a trial included

TSX Exchange Symbol: RVX

HAMBURG, Germany and CALGARY, AB, June 22 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX-208 at the European Atherosclerosis Society Congress (EAS) conference being held in Hamburg, Germany. The presentation titled "RVX-208 given orally raises plasma ApoA-I and HDL in human clinical trials," was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

"The data presented in Germany today further highlights that patients with low HDL/Apo-Al benefit most. For those patients in the highest risk category, subjects with low baseline HDL/Apo-Al, our data demonstrated that RVX-208 increased plasma levels of Apo-Al in the order of 13.25% compared to placebo. This data, combined with similar low baseline HDL/Apo A-l data analysis of the upcoming ASSERT trial data will further support the design of a very effective and efficient ASSURE trial," said Donald J. McCaffrey, President & CEO of Resverlogix.

Resverlogix recently completed a Phase 2 clinical trial called ASSERT to study RVX-208 an oral small molecule therapy for the treatment of atherosclerosis. The ASSERT trial enrolled subjects with stable coronary artery disease. A second planned Phase 2 trial, designated ASSURE, will include subjects with acute coronary syndrome and coronary artery disease of whom all will be examined with intravascular ultrasound (IVUS). Both the ASSERT and ASSURE studies are chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at the Cleveland Clinic.

Cardiovascular disease is the leading cause of death in the US and other developed nations costing the American health care system an estimated $448.5 billion in 2008. According to the American Heart Association's Heart Disease & Stroke Statistics 2010 publication, approximately every 25 seconds an American will have a coronary event and approximately every minute, someone will die from such an event. A key underlying cause of cardiovascular disease is atherosclerosis, a build-up of plaque in the arteries often referred to as 'hardening of the arteries'.

Apolipoprotein A-I (ApoA-I), the main protein component of high-density lipoprotein (HDL), represents the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that within the atherosclerotic plaques of the vessel wall to the liver for processing and excretion. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans. Developing small molecules that increase ApoA-I would satisfy a large unmet medical need.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 403-254-9252,
Email: Theresa@resverlogix.com;

Jun 16, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES/

TSX Symbol: RVX

CALGARY, June 16 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has entered into an agency agreement and has carried out an overnight marketed offering to sell up to approximately 3.1 million units (the "Units") at a price of CDN $3.23 per Unit, representing gross proceeds of up to $10 million. Each Unit is comprised of one common share and 0.4 of a common share purchase warrant. Each full warrant will have an exercise price of CDN $4.00, exercisable for a four year period commencing on the closing date of the offering. The offering is being conducted by Bloom Burton & Co. and Haywood Securities Inc., and is to be effected in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus dated April 20, 2010. Prior to the offering, Resverlogix had 48,828,376 common shares issued and outstanding.

This transaction is scheduled to close on or about June 22, 2010, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 403-254-9252,
Email: Theresa@resverlogix.com;

Jun 11, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES./

TSX Exchange Symbol: RVX

CALGARY, June 11 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today it has settled $200,000 of the previously announced draw down under its standby equity distribution agreement ("SEDA") with YA Global Master SPV Ltd. ("YA"). Under the draw down, Resverlogix issued 51,290 common shares to YA at a price of $ 3.90 per common share. In accordance with the terms of the SEDA, the common shares were issued at a discount of 5% to the volume weighted average price ("VWAP") of the common shares of Resverlogix traded on the Toronto Stock Exchange over the first two trading days following Resverlogix's notice of its intention to draw down on the SEDA on May 26, 2010.

Following the completion of the issuance of shares to YA, Resverlogix has 48,828,376 shares outstanding.

In connection with the draw down, Resverlogix will file a prospectus supplement to its short-form base shelf prospectus to qualify the shares issued to YA. Copies of the final short-form base shelf prospectus and prospectus supplement will be filed on SEDAR (www.sedar.com).

Securities Laws Matters

Securities legislation in the provinces of British Columbia, Alberta and Ontario provides purchasers with the right to withdraw from an agreement to purchase securities. This right may be exercised within two business days after receipt or deemed receipt of a prospectus and any amendment. The securities legislation further provides a purchaser with remedies for rescission or, in some jurisdictions, revisions of the price or damages if the prospectus and any amendment are not delivered to the purchaser, provided that the remedies for rescission, revisions of the price or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province. However, such rights and remedies will not be available to purchasers of Common Shares distributed under the short form base shelf prospectus, as supplemented by the prospectus supplement relating to the draw down, because the prospectus will not be delivered to purchasers, as permitted under a decision document issued by the Alberta Securities Commission on February 19, 2010.

The securities legislation further provides a purchaser with remedies for rescission or, in some jurisdictions, revisions of the price or damages if the prospectus and any amendment contains a misrepresentation, provided that the remedies for rescission, revisions of the price or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province. Such remedies remain unaffected by the non-delivery of the prospectus, as permitted under the decision document referred to above.

The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province for the particulars of these rights or consult with a legal adviser.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to the SEDA, future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp.,
Phone: 604-538-7072,
Fax: 403-256-8495,
Email: Theresa@resverlogix.com;

Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp.,
Phone: 403-254-9252,
Fax: 403-256-8495,
Email: Sarah@resverlogix.com

Jun 8, 2010

TSX Symbol: RVX

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES./

CALGARY, June 8 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has closed its previously announced prospectus offering of 2.8 million units (the "Units") at a price of CDN $3.30 per Unit for gross proceeds of $9.2 million (the "Offering"). Each Unit was comprised of one common share of the Company and 0.4 of a common share purchase warrant. Each full warrant is exercisable at a price of CDN $4.00 for a period of four years.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Jun 3, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES/

TSX Symbol: RVX

CALGARY, June 3 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that it has concluded its previously announced offering. Under the terms and conditions of the offering, Resverlogix will issue up to 2.8 million units (the "Units") at a price of CDN $3.30 per Unit, representing gross proceeds of up to $9.2 million. Each Unit will be comprised of one common share and 0.4 of a common share purchase warrant. Each full warrant will have an exercise price of CDN $4.00, exercisable for a four year period commencing on the closing date of the offering. The offering was conducted by Bloom Burton & Co. and Haywood Securities Inc., and is to be effected in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus dated April 20, 2010. Prior to the offering, Resverlogix had 45,977,086 common shares issued and outstanding.

This transaction is scheduled to close on or about June 8, 2010, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals. The securities are being offered in each of the provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus, dated April 20, 2010.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Jun 2, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES./

TSX Exchange Symbol: RVX

CALGARY, June 2 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today that it has entered into an agency agreement for an offering of units, each comprised of one common share and 0.4 of a common share purchase warrant, at a price of CDN $3.30 per unit. Each whole common share purchase warrant entitles the holder to acquire one common share of Resverlogix upon payment of CDN $4.00, exercisable for a four year period commencing on the closing date of the offering. The offering is being conducted by Bloom Burton & Co. and Haywood Securities Inc. The offering is to be effected in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus dated April 20, 2010.

The Company expects that this transaction will close on or about June 8, 2010, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals. The securities are being offered in each of the Canadian provinces of British Columbia, Alberta and Ontario by way of a prospectus supplement to Resverlogix's base shelf prospectus, dated April 20, 2010.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to, the current and/or future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

May 26, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES/

TSX Exchange Symbol: RVX

CALGARY, May 26 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today it has submitted to YA Global Master SPV Ltd. ("YA") a notice of its intention to draw down $1,000,000 under its previously announced standby equity distribution agreement ("SEDA"). In accordance with the provisions of the SEDA, YA will subscribe for common shares at a price equal to 95% of the daily volume weighted average price for the common shares for each of the ten consecutive trading days during the draw down pricing period. The drawdown and issuance of shares is subject to a minimum share price of $4.00 per share, below which YA shall not be required to subscribe. Based on the minimum share, the maximum number of shares to be issued under this drawdown is 263,158 shares.

On April 20, 2010, Resverlogix filed a final short form base shelf prospectus, copies of which are available on SEDAR (www.sedar.com). To qualify the shares issued to YA under the draw down, Resverlogix will file a prospectus supplement to its short form base shelf prospectus immediately following settlement.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to the SEDA, future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

May 12, 2010

Completion occurs 5 months ahead of schedule

TSX Exchange Symbol: RVX

CALGARY, May 12 /CNW/ - Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step forward in the development of this important cardiovascular drug. Our clinical team and our collaborators at the Cleveland Clinic will now spend the next few months assessing the study results to best plan for upcoming trials. The swift completion of the ASSERT study further allows us to make better assessments in identifying optimal dosing regimens moving forward," explained Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey continued, "Earlier studies have indicated that the drug worked best in those subjects with low HDL, therefore we will further assess if RVX-208 has a targeted effect in this high risk cardiovascular disease population. The rapid enrollment and dosing success for this trial was in large part due to having one organized Internal Review Board (IRB) for all 40 sites involved in the trial."

The ASSERT trial is a randomized, double-blind, placebo-controlled, multi-centered US study for 13 weeks of administration of RVX-208, which has enrolled 299 patients with stable coronary artery disease for a period of 13 weeks. The primary endpoint of the study is to determine if RVX-208 will produce an increase in plasma Apolipoprotein A-I (ApoA-I) levels compared to placebo group after three months of dosing. Other objectives are to examine the safety and tolerability of RVX-208 and to compare the dose and time response relationship for ApoA-I as well as to examine key reverse cholesterol markers involved with HDL functionality.

In related clinical news the parallel Phase 2 ASSURE trial for RVX-208, which announced its first site activation on February 25th, will be reassessing its enrollment procedure. Since the ASSERT trial provides us with data much faster than first anticipated, we can also now apply pertinent findings to the ASSURE trial. In order to expedite enrollment, while continuing our primary patient safety concerns, the ASSURE trial is being voluntarily halted on a temporary basis in order to modify enrollment procedures. "While the ASSERT trial set records for enrollment, the much more intricate ASSURE trial will not for the reason that the inclusion criteria is much more detailed and intensive. ASSURE currently requires a patient must have had a heart attack within the past four weeks. The patient is then required to voluntarily submit to having two invasive Intravascular Ultrasound (IVUS) both at the start and finish of the 90 day drug treatment period. We believe that we can enhance the enrollment procedure by modifying the inclusion criteria. One such option would be to include any patients sent to the Catheter Lab, thus greatly increasing the pool of patients that we would be able to draw from for enrolment in this trial. Patients will also now benefit from any added knowledge that we are about to gain from the successful completion of dosing in the ASSERT trial," stated Donald McCaffrey.

In other news today, Donald J. McCaffrey will be providing an updated corporate and clinical overview at 1:00 pm EDT. A slide presentation will be followed by a question and answer session regarding the impact of the early completion of the ASSERT trial and the enhancement of enrollment procedures for the ASSURE trial.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix100511.html.

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, stable Coronary Artery Disease, Acute Coronary Syndrome and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release

%SEDAR: 00019253E

May 10, 2010

TSX Exchange Symbol: RVX

CALGARY, May 10 /CNW/ - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Wednesday, May 12, 2010 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to provide a corporate and clinical update. There will be a slide presentation followed by a question and answer session regarding the impact of the early completion of the ASSERT trial in addition to an update of the ASSURE trial.

The dial-in numbers for this event are toll free 1-800-319-4610 and international 1-604-638-5340. A link for this webcast will be posted onto the homepage of Resverlogix's website and can be accessed from the following address http://services.choruscall.com/links/resverlogix100511.html.

The webcast will be available on the Resverlogix website for replay for a period of 45 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Apr 9, 2010

TSX Exchange Symbol: RVX

SAN FRANCISCO and CALGARY, April 9 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology (ATVB) conference being held in San Francisco, California. The presentation titled "RVX-208, an Orally Active Small Molecule, Raises ApoA-I Production and HDL Levels in Human Trials and Also Reduces Plaque Numbers in a Mouse Model of Atherosclerosis" was presented by Dr. Norman Wong, MD, Chief Scientific Officer of Resverlogix.

Resverlogix's oral small molecule therapy for the treatment of atherosclerosis is currently being studied in two parallel Phase 2 clinical trials. The first trial focuses on stable coronary artery disease patients, while the second trial examines patients with unstable acute coronary syndrome and includes the use of intravascular ultrasound (IVUS). Both of these studies are chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at the Cleveland Clinic.

Cardiovascular disease is the leading cause of death in the US and other developed nations costing the American health care system an estimated $448.5 billion in 2008. According to the American Heart Association's Heart Disease & Stroke Statistics 2010 publication, approximately every 25 seconds an American will have a coronary event and approximately every minute, someone will die from such an event. A key underlying cause of cardiovascular disease is atherosclerosis, a build-up of plaque in the arteries often referred to as 'hardening of the arteries'.

Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL), represents the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that within the atherosclerotic plaques of the vessel wall to the liver for processing. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibits progression and induces regression of atherosclerosis in animals and humans. Developing small molecules that increase ApoA-I would satisfy a vast unmet medical need.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, stable Coronary Artery Disease, Acute Coronary Syndrome and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Mar 29, 2010

/THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH US NEWSWIRE SERVICES./

TSX Exchange Symbol: RVX

CALGARY, March 29 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces today that it has activated its standby equity distribution agreement ("SEDA") with YA Global Master SPV, Ltd. ("YA Global"), a fund managed by Yorkville Advisors, LLC, whereby Resverlogix has the option, at its sole discretion, to issue and sell, and YA Global is committed to purchase, up to CAD $25 million of common shares from treasury.

Under the SEDA, Resverlogix can draw on YA Global's commitment by submitting draw down notices from time to time. Each draw down notice is subject to a maximum amount of $500,000, as well as a minimum price below which the Company will not issue shares to YA Global. Subject to the applicable minimum price, the purchase price of the newly issued shares will be calculated based on a 5% discount of the market price of the Company's common shares; the shares will be qualified by prospectus and, as such, not subject to a hold period. The SEDA does not prevent Resverlogix from pursuing other financings and the SEDA can be terminated at any time by the Company without the payment of any additional fees. Full details of the terms and conditions of this agreement have been disclosed on SEDAR.

"As announced in December, the purpose of this financing vehicle is to provide Resverlogix with the ability to access strategic amounts of capital at its sole discretion. Resverlogix is in a nice position where we have access to readily available and flexible capital while continuing to review other finance related opportunities," said Donald J. McCaffrey, President and CEO of Resverlogix.

"We are very excited by our investment in Resverlogix and their novel approach and platform for development of new treatments for cardiovascular disease," said Dr. Michael J. Nowak, Managing Director at Yorkville Advisors, LLC.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

About Yorkville Advisors

Yorkville Advisors, LLC is the investment manager to a family of funds, which specializes in providing flexible, innovative finance investments in publicly listed companies worldwide. Pioneered nine years ago by Yorkville, a SEDA offers companies a cost effective way to raise capital to fund their business plans, growth strategies, or other corporate uses. Yorkville has offices in Jersey City, New Jersey; Jupiter, Florida; Denver, Colorado; London and Hong Kong. It also has joint venture agreements in Italy, Israel and Greece. For further information please visit www.yorkvilleadvisors.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to the SEDA, future financings, research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the January 31, 2010 MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Mar 5, 2010

TSX Exchange Symbol: RVX

CALGARY, March 5 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), reports that in the March 5th, 2010 press release issued by the Company, where Resverlogix quoted an article written by BusinessWeek, Resverlogix would like to clarify that the article was written by Bloomberg BusinessWeek.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the most recent MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Mar 5, 2010

TSX Exchange Symbol: RVX

CALGARY, March 5 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), at the request of the Investment Industry Regulatory Organization of Canada (IIROC) on the behalf of the Toronto Stock Exchange (TSX), would like to make a brief statement regarding the recent increase in stock volume and price. Resverlogix management believes the recent increases are due to the underlying importance of recent public announcements as well as increased public awareness of the company due to an article written by BusinessWeek. Management is not aware of any non-public information related to the increase.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the most recent MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

Feb 25, 2010

Cleveland Clinic coordinates IVUS testing of RVX-208 in acute coronary syndrome patients

CALGARY, Feb. 25 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment. The study is chaired by Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of Cardiovascular Medicine and the principal investigator is Dr. Stephen Nicholls, Medical Director of Intravascular Ultrasound at Cleveland Clinic. The Cleveland Clinic has named this trial, ASSURE 1, an acronym for ApoA-l Synthesis Stimulation in Acute Coronary Syndrome patients. The ASSURE 1 study compliments the ongoing ASSERT trial in patients with stable coronary artery disease.

"For the first time Resverlogix anticipates that it will be able to describe early trends for the relationship between RVX-208 and changes in lipid parameters, changes in measures of atheroma burden and plaque composition," said Dr. Jan O. Johansson, M.D., PhD., Senior Vice President Medical Affairs of Resverlogix. Johansson emphasized, "The unmet medical need in coronary atherosclerosis worldwide is huge. The importance of the reduction of atheroma burden via ApoA-l therapies was highlighted in a recent pharmacoeconomic analysis authored by Destum Partners. Destum's research concluded that by using an ApoA-l increasing therapy in patients as a secondary prevention measure, outcomes could be significantly improved and the potential savings to the US health care system, society, and employers beyond current standard of care are from US $22.9 billion and US $76.8 billion annually, for a 1% to 5% regression of atherosclerosis, respectively."

This IVUS study is comprised of 15-20 US sites will dose approximately 120 ACS patients on standard of care therapy and examine lipid effects by RVX-208 compared to placebo control. In half of the patients a change in atherosclerosis will be assessed, i.e. change in plaque volume and plaque composition. The primary objective of this study is to determine the 3 month effect of RVX-208 on change in the plasma levels of ApoA-l in patients with a recent ACS event who require coronary angiography versus placebo. The secondary objectives for this study include assessing the safety and tolerability of the drug through evaluation of adverse events as well as to evaluate the effect of RVX-208 on other lipid parameters.

"There are a number of people who are very pleased that we are able to announce the beginning of our IVUS study. Much planning has been undertaken with our international experts who reside on our IVUS Steering Committee and Clinical Advisory Committee. We are pleased to be able to bring RVX-208 to acute coronary syndrome patients, a group that presents with high cardiovascular risk," said Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix Corp.

Resverlogix clinical program is expanding. In unrelated news Resverlogix is pleased to announce today the appointment of Ms. Tina Rarick to the position of Vice President Project Management & Business Operations. Tina recently joined Resverlogix after working for the past six years as a Global Project Manager for Roche Pharmaceuticals. Previous to this Tina was with several pharmaceutical firms including Schering-Plough and SUGEN/Pharmacia. Earlier in her career Tina spent her time in the laboratory as a biologist with Genentech and the University of Utah.

Tina has fifteen years of combined experience working in diverse corporate cultures from start-ups to multinationals. In the last 10 years she has worked in Global Project Management where she was primarily accountable for team leadership, strategic planning and financial management. Some of her key strengths are leading cross-functional internal and partnered global development teams in accomplishing business driven milestones on time and within budget. Tina received her B.S. from the University of Utah and her MBA from Duke University

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our statements with respect to vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Additionally, risks and uncertainties are discussed in detail in the most recent MD&A. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

%SEDAR: 00019253E